<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">11566</article-id><article-id pub-id-type="doi">10.7554/eLife.11566</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Registered Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Human Biology and Medicine</subject></subj-group></article-categories><title-group><article-title>Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-42300"><name><surname>Sharma</surname><given-names>Vidhu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-42151"><name><surname>Young</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-42152"><name><surname>Allison</surname><given-names>Anne B</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-29160"><name><surname>Owen</surname><given-names>Kate</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><collab>Reproducibility Project: Cancer Biology</collab><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution>Applied Biological Materials</institution>, <addr-line><named-content content-type="city">Richmond</named-content></addr-line>, <country>Canada</country></aff><aff id="aff2"><label>2</label><institution>Piedmond Virginia Community College</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution>University of Virginia</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hunter</surname><given-names>Tony</given-names></name><role>Reviewing editor</role><aff id="aff4"><institution>Salk Institute</institution>, <country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Iorns</surname><given-names>Elizabeth</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Gunn</surname><given-names>William</given-names></name><aff><institution>Mendeley</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Tan</surname><given-names>Fraser</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Lomax</surname><given-names>Joelle</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Perfito</surname><given-names>Nicole</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alot</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Errington</surname><given-names>Timothy</given-names></name><aff><institution>Center for Open Science</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>nicole@scienceexchange.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>02</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e11566</elocation-id><history><date date-type="received"><day>15</day><month>09</month><year>2015</year></date><date date-type="accepted"><day>08</day><month>01</month><year>2016</year></date><fn><p><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kan</surname><given-names>Z</given-names></name><name><surname>Jaiswal</surname><given-names>BS</given-names></name><name><surname>Stinson</surname><given-names>J</given-names></name><name><surname>Janakiraman</surname><given-names>V</given-names></name><name><surname>Bhatt</surname><given-names>D</given-names></name><name><surname>Stern</surname><given-names>HM</given-names></name><name><surname>Yue</surname><given-names>P</given-names></name><name><surname>Haverty</surname><given-names>PM</given-names></name><name><surname>Bourgon</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Moorhead</surname><given-names>M</given-names></name><name><surname>Chaudhuri</surname><given-names>S</given-names></name><name><surname>Tomsho</surname><given-names>LP</given-names></name><name><surname>Peters</surname><given-names>BA</given-names></name><name><surname>Pujara</surname><given-names>K</given-names></name><name><surname>Cordes</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>DP</given-names></name><name><surname>Carlton</surname><given-names>VEH</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Eigenbrot</surname><given-names>C</given-names></name><name><surname>Kaminker</surname><given-names>JS</given-names></name><name><surname>Eberhard</surname><given-names>DA</given-names></name><name><surname>Waring</surname><given-names>P</given-names></name><name><surname>Schuster</surname><given-names>SC</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Stokoe</surname><given-names>D</given-names></name><name><surname>de Sauvage</surname><given-names>FJ</given-names></name><name><surname>Faham</surname><given-names>M</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name></person-group> . <day>12</day><month>08</month><year iso-8601-date="2010">2010</year> . <article-title>Diverse somatic mutation patterns and pathway alterations in human cancers</article-title> .<source>Nature</source> . <volume>466</volume> . <fpage>869</fpage> – <lpage>873</lpage> . doi: <pub-id pub-id-type="doi">10.1038/nature09208</pub-id> .</mixed-citation> </p></fn></history><permissions><copyright-statement>© 2016, Sharma et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Sharma et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-11566-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.11566.001</object-id><p>The <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/home/">Reproducibility Project: Cancer Biology</ext-link> seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/studies/">citations and Altmetric scores</ext-link> (<xref ref-type="bibr" rid="bib12">Errington et al., 2014</xref>). This Registered Report describes the proposed replication plan of key experiments from &quot;Diverse somatic mutation patterns and pathway alterations in human cancers&quot; by Kan and colleagues published in <italic>Nature</italic> in 2010 (<xref ref-type="bibr" rid="bib24">Kan et al., 2010</xref>). The experiments to be replicated are those reported in Figures 3D-F and 4C-F. Kan and colleagues utilized mismatch repair detection (MRD) technology to identify somatic mutations in primary human tumor samples and identified a previously uncharacterized arginine 243 to histidine (R243H) mutation in the G-protein α subunit <italic>GNAO1</italic> in breast carcinoma tissue. In Figures 3D-F, Kan and colleagues demonstrated that stable expression of mutant <italic>GNAO1<sup>R243D</sup></italic> conferred a significant growth advantage in human mammary epithelial cells, confirming the oncogenic potential of this mutation. Similarly, expression of variants with somatic mutations in <italic>MAP2K4</italic>, a JNK pathway kinase (shown in Figures 4C-E) resulted in a significant increase in anchorage-independent growth. Interestingly, these mutants exhibited reduced kinase activity compared to wild type <italic>MAP2K4</italic>, indicating these mutations impose a dominant-negative influence to promote growth (Figure 4F). The Reproducibility Project: Cancer Biology is a collaboration between the <ext-link ext-link-type="uri" xlink:href="http://centerforopenscience.org/">Center for Open Science</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.scienceexchange.com/">Science Exchange</ext-link> and the results of the replications will be published in <italic>eLife</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11566.001">http://dx.doi.org/10.7554/eLife.11566.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>methodology</kwd><kwd>Reproducibility Project: Cancer Biology</kwd><kwd>MAP kinase kinase 4</kwd><kwd>somatic mutation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Laura and John Arnold Foundation</institution></institution-wrap></funding-source><principal-award-recipient><institution>The Reproducibility Project: Cancer Biology Core Team</institution></principal-award-recipient></award-group><funding-statement>The Reproducibility Project: Cancer Biology is funded by the Laura and John Arnold Foundation, provided to the Center for Open Science in collaboration with Science Exchange. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Human cancer is driven by the acquisition of mutations in cells of somatic origin. Somatic mutations comprise several distinct classes of DNA sequence changes, including single-nucleotide substitutions, small insertions and deletions (indels), copy number alterations, and structural rearrangements (<xref ref-type="bibr" rid="bib47">Weir et al., 2007</xref>; <xref ref-type="bibr" rid="bib5">Chin and Gray, 2008</xref>; <xref ref-type="bibr" rid="bib38">Stratton et al., 2009</xref>; <xref ref-type="bibr" rid="bib35">Pleasance et al., 2010</xref>). Somatic mutations can be further characterized based on their oncogenic ability: genetic variations that are directly involved in cancer development are termed “driver” mutations, whereas mutations that do not confer any obvious advantage are referred to as “passenger” mutations (<xref ref-type="bibr" rid="bib9">Davies et al., 2005</xref>). In all cases, genetic changes in somatic cells arise as a result of defective DNA repair mechanisms and/or imprecise DNA replication, and can develop spontaneously, be acquired over the lifetime of an individual, or by direct exposure to mutagens, such as tobacco smoke and ionizing UV radiation (<xref ref-type="bibr" rid="bib34">Pfeifer, 2010</xref>; <xref ref-type="bibr" rid="bib35">Pleasance et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Helleday et al., 2014</xref>). Over the past 10 years, technologies for the detection of wide-spread genetic alterations have been developed and used to analyze cancer genomes (<xref ref-type="bibr" rid="bib38">Stratton et al., 2009</xref>; <xref ref-type="bibr" rid="bib45">Watson et al., 2013</xref>). Its is clear that cancer cell genomes often harbor substantial somatic mutation burdens, thus the ability to generate a comprehensive genetic cancer profile has the potential to significantly improve patient diagnosis and treatment.</p><p>The combination of PCR and Sanger sequencing to identify mutations in tumor genomes has proven to be a powerful approach in the study of cancer genomics (<xref ref-type="bibr" rid="bib7">Collins et al., 2003</xref>). However, this technology is constrained by limited throughput and cost (<xref ref-type="bibr" rid="bib6">Chin et al., 2011</xref>). Here, Kan and colleagues utilized mismatch repair detection (MRD) technology as a low-cost, high throughput alternative to identify somatic mutations in a large number of primary human tumor samples (<xref ref-type="bibr" rid="bib33">Peters et al., 2007</xref>). Using this technique, Kan and colleagues identified an uncharacterized somatic mutation in <italic>GNAO1</italic> from breast carcinoma tissue (<xref ref-type="bibr" rid="bib24">Kan et al., 2010</xref>). <italic>GNAO1</italic> encodes the Gαo subunit of heterotrimeric guanine-binding proteins (G proteins) (<xref ref-type="bibr" rid="bib22">Jastrzebska, 2013</xref>). G proteins function as molecular switches that alternate between “on” (GTP-bound) and “off” (GDP-bound) states to control signal transduction in eukaryotes (<xref ref-type="bibr" rid="bib17">Gilman, 1987</xref>; <xref ref-type="bibr" rid="bib3">Birnbaumer, 2007b</xref>; <xref ref-type="bibr" rid="bib2">2007a</xref>). While previous studies have reported oncogenic mutations in the Gα subunits of other G proteins, including <italic>GNAS, GNAI2</italic> and <italic>GNAQ</italic> (<xref ref-type="bibr" rid="bib25">Landis et al., 1989</xref>; <xref ref-type="bibr" rid="bib29">Lyons et al., 1990</xref>; <xref ref-type="bibr" rid="bib15">Forbes et al., 2008</xref>; <xref ref-type="bibr" rid="bib43">Van Raamsdonk et al., 2009</xref>), the arginine 243 to histidine (R243H) conversion identified in <italic>GNAO1</italic> does not correspond to any previously described mutations within G proteins (<xref ref-type="bibr" rid="bib16">Garcia-Marcos et al., 2011</xref>). In Figure 3D–F, the oncogenic potential of this mutation was tested. Human mammary epithelial cells (HMECs) stably expressing equivalent levels of wild type <italic>GNAO1</italic> or <italic>GNAO1</italic><sup><italic>R243H</italic></sup> were suspended in agar before assessment for colony formation. This key experiment reported that the R243H mutation promotes a two-fold increase in anchorage-independent growth compared to cells expressing wild type <italic>GNAO1</italic>, and will be replicated in Protocol 1. Subsequent work on <italic>GNAO1</italic> has characterized the molecular basis underlying the oncogenic properties of the R243H mutation. Importantly, these studies have determined that the R243H mutation renders Gαo constitutively active via Src-STAT3 signaling (<xref ref-type="bibr" rid="bib16">Garcia-Marcos et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Leyme et al., 2014</xref>).</p><p>Kan and colleagues also identified a number of somatic mutations in mitogen activated protein kinase kinase 4 (<italic>MAP2K4</italic>) (<xref ref-type="bibr" rid="bib24">Kan et al., 2010</xref>). MAP2K4 is a component of a triple kinase cascade that involves the successive activation of downstream MAP kinases, culminating in the activation of c-Jun NH2-terminal kinases (JNK) and p38 (<xref ref-type="bibr" rid="bib11">Derijard et al., 1995</xref>; <xref ref-type="bibr" rid="bib4">Chang and Karin, 2001</xref>; <xref ref-type="bibr" rid="bib23">Johnson and Lapadat, 2002</xref>). Both the JNK and p38 signaling pathways mediate cellular responses to cytokine signals, stress and other extracellular stimuli (<xref ref-type="bibr" rid="bib23">Johnson and Lapadat, 2002</xref>). While mutations in <italic>MAP2K4</italic> have been reported here (<xref ref-type="bibr" rid="bib24">Kan et al., 2010</xref>) and elsewhere (<xref ref-type="bibr" rid="bib42">Teng et al., 1997</xref>; <xref ref-type="bibr" rid="bib31">Parsons et al., 2005</xref>; <xref ref-type="bibr" rid="bib18">Greenman et al., 2007</xref>; <xref ref-type="bibr" rid="bib15">Forbes et al., 2008</xref>), the role of <italic>MAP2K4</italic> in cancer has remained complex and contradictory. Some studies have suggested <italic>MAP2K4</italic> functions as a pro-oncogenic molecule in breast and pancreatic tumors (<xref ref-type="bibr" rid="bib44">Wang et al., 2004</xref>), melanoma (<xref ref-type="bibr" rid="bib14">Finegan and Tournier, 2010</xref>), and in prostate cancer tumors (<xref ref-type="bibr" rid="bib28">Lotan et al., 2007</xref>; <xref ref-type="bibr" rid="bib32">Pavese et al., 2014</xref>), whereas other early reports identified <italic>MAP2K4</italic> as a putative tumor suppressor gene due to its frequent inactivation in human cancer cell lines and tumor tissues, including pancreatic, breast, ovarian, and colon cancer cells and tissues (<xref ref-type="bibr" rid="bib39">Su et al., 1998</xref>; <xref ref-type="bibr" rid="bib40">2002</xref>; <xref ref-type="bibr" rid="bib30">Nakayama et al., 2006</xref>; <xref ref-type="bibr" rid="bib1">Ahn et al., 2011</xref>).</p><p>In Figure 4C–E, the functional relevance of six select <italic>MAP2K4</italic> mutants (5 located in the kinase domain, 1 outside the kinase domain) were tested <italic>in vitro</italic> (<xref ref-type="bibr" rid="bib24">Kan et al., 2010</xref>). NIH3T3 fibroblasts stably expressing equivalent levels of either WT or mutant <italic>MAP2K4</italic> were assessed for their ability to promote anchorage-independent growth. Importantly, all six <italic>MAP2K4</italic> variants resulted in significantly enhanced agar colony formation compared to cells expressing wild type <italic>MAP2K4</italic>. A majority of the <italic>MAP2K4</italic> mutants resulted in reduced activity to either JNK or myelin basic protein (MBP) when tested in an <italic>in vitro</italic> kinase assay suggesting that reduced MAP2K4 signaling plays a dominant-negative role in the control of cell growth. A related study examined the invasiveness of cells where endogenous <italic>MAP2K4</italic> was depleted and various <italic>MAP2K4</italic> mutants were added back, including four of the mutants tested by Kan and colleagues (<xref ref-type="bibr" rid="bib1">Ahn et al., 2011</xref>). The effect on invasion was directly proportional to the kinase activities of the mutants. The mutations that resulted in loss-of-function kinase activity (including R154W, S251N, and N234I examined by Kan and colleagues) resulted in increased invasion, while mutations with gain-of-function kinase activity, or comparable kinase activity to wild-type (including A279T examined by Kan and colleagues), did not (<xref ref-type="bibr" rid="bib1">Ahn et al., 2011</xref>). More recent studies have confirmed these findings, showing that <italic>MAP2K4</italic> genetic inactivation is prevalent in high grade serous and endometrioid carcinomas, breast cancer, and pancreatic cancer (<xref ref-type="bibr" rid="bib10">Davis et al., 2011</xref>; <xref ref-type="bibr" rid="bib49">Yeasmin et al., 2011b</xref>; <xref ref-type="bibr" rid="bib48">Yeasmin et al., 2011a</xref>; <xref ref-type="bibr" rid="bib8">Curtis et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Huang et al., 2013</xref>). Furthermore, genetic polymorphisms that increase <italic>MAP2K4</italic> promoter activity are associated with reduced risk of prostate, lung, and sporadic colorectal cancers (<xref ref-type="bibr" rid="bib46">Wei et al., 2009</xref>; <xref ref-type="bibr" rid="bib27">Liu et al., 2010</xref>; <xref ref-type="bibr" rid="bib37">Shao et al., 2012</xref>). A recent study by Haeusgen and colleagues (<xref ref-type="bibr" rid="bib19">Haeusgen et al., 2014</xref>) suggests that the balance between <italic>MAP2K4</italic> and a novel <italic>MAP2K4 </italic>splice variant may be important in regulating appropriate cell growth. The key experiments described in Figures 4C–F will be replicated in Protocol 2.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><p>Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (#) indicates information provided by the replicating lab.</p><sec id="s2-1"><title>Protocol 1: Generation of N-terminally Flag-tagged <italic>MAP2K4</italic> and <italic>GNAO1</italic> wild-type and mutant vectors</title><p>This protocol generates N-terminally flag-tagged wild type or mutant <italic>GNAO1</italic> and wild type or mutant <italic>MAP2K4</italic> vectors. These vectors will be used in Protocols 2 and 4.</p><sec id="s2-1-1"><title>Sampling</title><list list-type="bullet"><list-item><p>This experiment will be performed once in order to generate vectors.</p></list-item></list></sec><sec id="s2-1-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>pRetroX-IRES-ZsGreen1 Vector</td><td>Plasmid</td><td>Clontech</td><td>632520</td><td>Original product number not specified; <break/>replaces pRetro-IRES-GFP-Vector</td></tr><tr><td><italic>MAP2K4<sup>WT</sup></italic> Myc-DDK tagged –includes FLAG tag<sup>1</sup></td><td>Plasmid</td><td>Origene</td><td>RC206051</td><td>Original product number not specified</td></tr><tr><td><italic>GNAO1<sup>WT</sup></italic> Myc-DDK tagged (Variant 1) – includes FLAG tag<sup>1</sup></td><td>Plasmid</td><td>Origene</td><td>RC217958</td><td>Original product number not specified</td></tr><tr><td>Agilent - QuikChange Lightning Multi Site-Directed Mutagenesis Kit</td><td>Kit</td><td>Agilent</td><td>210516</td><td>Original product number not specified</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p><sup>1</sup>DDK is equivalent to FLAG which is a registered trademark of Sigma Aldrich</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-1-3"><title>Procedure</title><list list-type="order"><list-item><p>1. Generate <italic>GNAO1</italic> and <italic>MAP2K4</italic> mutant constructs:<list list-type="alpha-lower"><list-item><p>Perform site-directed mutations on cDNA ORFs using <sup>#</sup>Agilent QuikChange Kit according to manufacturer’s protocol.<list list-type="roman-lower"><list-item><p>Point mutations:<list list-type="order"><list-item><p><italic>GNAO1</italic>: arginine 243 to histidine (R243H)</p></list-item><list-item><p><italic>MAP2K4</italic>: arginine 228 to lysine (R228K)</p></list-item><list-item><p><italic>MAP2K4</italic>: alanine 279 to threonine (A279T)</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Clone inserts (includes FLAG tag) into <sup>#</sup>pRetroX-IRES-ZsGreen1 vector backbone according to manufacturer’s protocols.<list list-type="alpha-lower"><list-item><p>Specific molecular cloning steps and reagents used will be recorded and reported later.</p></list-item><list-item><p><sup>#</sup>Perform PCR cloning using primers that encompass the ORF and FLAG-tag insert from the original cDNA</p></list-item></list></p></list-item><list-item><p>Sequence vectors to confirm identity as well as mutational status, and run on gel to confirm integrity. [additional QC]<list list-type="alpha-lower"><list-item><p><sup>#</sup>Use the following sequencing primers:<list list-type="roman-lower"><list-item><p><italic>GNAO1<sup>R243H </sup></italic>Forward: GCCCTTTTTGAGTTTGGATC</p></list-item><list-item><p><italic>GNAO<sup>R243H</sup></italic> Reverse: GTAAAGCATGTGCACCGAGG</p></list-item><list-item><p><italic>MAP2K4<sup>R228K</sup></italic> Forward: GCCCTTTTTGAGTTTGGATC</p></list-item><list-item><p><italic>MAP2K4<sup>R228K</sup></italic> Reverse: GTAAAGCATGTGCACCGAGG</p></list-item><list-item><p><italic>MAP2K4<sup>A279T</sup></italic> Forward: GCCCTTTTTGAGTTTGGATC</p></list-item><list-item><p><italic>MAP2K4<sup>A279T</sup></italic> Reverse: GTAAAGCATGTGCACCGAGG</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-1-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected<list list-type="bullet"><list-item><p>Sequencing information and gel verification of vectors</p></list-item></list></p></list-item></list><list list-type="bullet"><list-item><p>Sample delivered for further analysis:<list list-type="bullet"><list-item><p>Plasmids for use in Protocols 2 and 4:<list list-type="bullet"><list-item><p>pRetroX-IRES-ZsGreen1</p></list-item><list-item><p>pRetroX-FLAG-<italic>GNAO1<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>pRetroX-FLAG-<italic>GNAO1<sup>R243H</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>pRetroX-FLAG-<italic>MAP2K4<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>pRetroX-FLAG-<italic>MAP2K4<sup>R228K</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>pRetroX-FLAG-<italic>MAP2K4<sup>A279T</sup></italic>-IRES-ZsGreen1</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-1-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>None applicable.</p></list-item></list></sec><sec id="s2-1-6"><title>Known differences from the original study</title><p>The vector backbone pRetroX-IRES-ZsGreen1 will be used instead of pRetroX-IRES-FLAG because the latter is no longer available. The replicating lab will use a cDNA with an ORF tagged with myc-DDK (the same as FLAG) for downstream protocols. Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-1-7"><title>Provisions for quality control</title><p>Sequencing and gel analysis of plasmids will be reported. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/jpeqg/">https://osf.io/jpeqg/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-2"><title>Protocol 2: Generation of human mammary epithelial cells stably expressing wild-type or GNAO1<sup>R243H</sup></title><p>This protocol describes the generation of HMECs stably expressing WT or mutant GNAO1<sup>R243H</sup> protein. Expression of GNAO1 will be confirmed by Western blot that will be a replication of Figure 3F. These cells will subsequently be used in Protocol 3.</p><sec id="s2-2-1"><title>Sampling</title><list list-type="bullet"><list-item><p>This experiment to be conducted one time to confirm stable expression of GNAO1<sup>WT</sup> or GNAO1<sup>R243H</sup> protein.</p></list-item><list-item><p>The experiment has 4 cohorts:<list list-type="bullet"><list-item><p>Cohort 1: Uninfected HMECs [additional negative control]</p></list-item><list-item><p>Cohort 2: HMECs transduced with pRetroX-IRES-ZsGreen1 -empty vector [additional negative control]</p></list-item><list-item><p>Cohort 3: HMECs transduced with pRetroX-FLAG-<italic>GNAO1<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>Cohort 4: HMECs transduced with pRetroX-FLAG-<italic>GNAO1<sup>R243H</sup></italic>-IRES-ZsGreen1</p></list-item></list></p></list-item><list-item><p>Western blotting will be performed for the following proteins:<list list-type="bullet"><list-item><p>FLAG</p></list-item><list-item><p>β-ACTIN</p></list-item></list></p></list-item></list></sec><sec id="s2-2-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>pRetroX-IRES-ZsGreen1 vector</td><td>Plasmid</td><td colspan="3">Produced in Protocol 1</td></tr><tr><td>pRetroX- FLAG-<italic>GNAO1<sup>WT</sup></italic> <break/>-IRES-ZsGreen1 vector</td><td>Plasmid</td><td colspan="3">Produced in Protocol 1</td></tr><tr><td>pRetroX-FLAG-<italic>GNAO1<sup>R243H</sup></italic> <break/>-IRES-ZsGreen1 vector</td><td>Plasmid</td><td colspan="3">Produced in Protocol 1</td></tr><tr><td>HMECs</td><td>Cell line</td><td>ATCC</td><td>PCS-600-010</td><td>Original product number not specified; <break/>Replaces Life Technology brand used <break/>in original study</td></tr><tr><td>HMEC medium</td><td>Cell culture</td><td>ATCC</td><td>PCS-600-03</td><td>Original product number not specified; <break/>Replaces Life Technology brand used <break/>in original study</td></tr><tr><td>HMEC supplement</td><td>Cell culture</td><td>ATCC</td><td>PCS-600-040</td><td>Original product number not specified; <break/>Replaces Life Technology brand used <break/>in original study</td></tr><tr><td>Bovine pituitary extract</td><td>Cell culture</td><td>Life Technologies</td><td>13028014</td><td/></tr><tr><td>Penicillin/Streptomycin</td><td>Cell culture</td><td>Applied Biological Materials</td><td>G255</td><td>Original not specified</td></tr><tr><td>Phoenix amphoteric cells</td><td>Cell line</td><td>ATCC</td><td>ATCC CRL-3213</td><td>Replaces Orbigen brand <break/>used in original study</td></tr><tr><td>DMEM</td><td>Cell culture</td><td>Sigma</td><td>11965-092</td><td>Original not specified</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture</td><td>Life Technologies</td><td>12483-020</td><td>Original not specified</td></tr><tr><td>L-glutamine</td><td>Cell culture</td><td>Life Technologies</td><td>35050-061</td><td>Original not specified</td></tr><tr><td>Glucose</td><td>Cell culture</td><td>Life Technologies</td><td>A2494001</td><td>Original not specified</td></tr><tr><td>Lipofectamine 2000</td><td>Transfection Reagent</td><td>Life Technologies</td><td>11668027</td><td/></tr><tr><td>Opti-MEM</td><td>Transfection Reagent</td><td>Sigma-Aldrich</td><td>31985070</td><td>Original not specified</td></tr><tr><td>PBS</td><td>Buffer</td><td>GIBCO</td><td>10010023</td><td>Original not specified</td></tr><tr><td>0.45 µm syringe filter</td><td>Labware</td><td>Millipore</td><td>SLHV033RB</td><td>Original not specified</td></tr><tr><td>Trypsin EDTA</td><td>Buffer</td><td>ABM</td><td>TM050</td><td>Original not specified</td></tr><tr><td>FBS</td><td>Buffer</td><td>GIBCO</td><td>12483</td><td>Original not specified</td></tr><tr><td>SDS</td><td>Chemical</td><td colspan="3" rowspan="5">Left to the discretion of the replicating lab</td></tr><tr><td>2-mercaptoethanol</td><td>Chemical</td></tr><tr><td>Glycerol</td><td>Chemical</td></tr><tr><td>bromophenol blue</td><td>Chemical</td></tr><tr><td>Tris-HCl</td><td>Chemical</td></tr><tr><td>Bradford Assay</td><td>Detection assay</td><td>Sigma</td><td>B6916-500 ML</td><td>Original not specified</td></tr><tr><td>12% SDS-PAGE gel</td><td>Western Blot Reagent</td><td>Invitrogen</td><td>EC60252BOX</td><td>Original 4–20%</td></tr><tr><td>OptiProtein Marker</td><td>Western Blot Reagent</td><td>Applied Biological Materials</td><td>G252</td><td>Original not specified</td></tr><tr><td>PVDF membrane</td><td>Western Blot Reagent</td><td>Biorad</td><td>162-0015</td><td>Original Nitrocellulose</td></tr><tr><td>Skim milk powder</td><td>Western Blot Reagent</td><td>Fisher Scientific</td><td>361021617</td><td>Original not specified</td></tr><tr><td>1X TBS solution</td><td>Buffer</td><td>Fisher Scientific</td><td>BP2471-100</td><td>Original not specified</td></tr><tr><td>Anti-FLAG M2 antibody</td><td>Antibody</td><td>Sigma</td><td>F1804</td><td/></tr><tr><td>Anti-ß-ACTIN antibody</td><td>Antibody</td><td>Abcam</td><td>Ab8227</td><td>Original not specified</td></tr><tr><td>Anti-mouse HRP-conjugated <break/>secondary antibody</td><td>Antibody</td><td>Abcam</td><td>Ab6728</td><td>Original not specified</td></tr><tr><td>ECL Reagent A and B</td><td>Western Blot Reagent</td><td>Applied Biological Materials</td><td>G075</td><td>Replaces Thermo <break/>Fisher brand.</td></tr><tr><td>X-ray Film</td><td>Western Blot Reagent</td><td>Kodak</td><td>XBT-1</td><td>Original not specified</td></tr></tbody></table></table-wrap></sec><sec id="s2-2-3"><title>Procedure</title><p>Notes:</p><list list-type="bullet"><list-item><p>HMECs are grown in complete HMEC medium: HMEC medium supplemented with HMEC supplement, <sup>#</sup>0.05 mg/mL bovine pituitary extract, 100 U/mL penicillin and 100 mg/ml streptomycin cultured at 37°C and 5% CO<sub>2</sub>.</p></list-item><list-item><p>Phoenix cells are grown in complete DMEM medium: DMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine and 4.5 g/L glucose, 100 U/mL penicillin and 100 mg/ml streptomycin cultured at 37°C and 5% CO<sub>2</sub>.</p></list-item><list-item><p>All cells will be sent for mycoplasma testing and STR profiling.</p></list-item></list><list list-type="order"><list-item><p><sup>#</sup>Transfect Phoenix cells with the appropriate retroviral constructs using Lipofectamine 2000 according to manufacturer’s instructions.<list list-type="alpha-lower"><list-item><p>On the day before transfection, transfer Phoenix cells to fresh medium in 6 well plates and maintain at 37°C and 5% CO<sub>2</sub>.</p></list-item><list-item><p>On the day of transfection, dilute 2.5 µg plasmid DNA in 500 µl Opti-MEM medium and mix gently.<list list-type="roman-lower"><list-item><p>pRetroX-FLAG-<italic>GNAO1<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>pRetroX-FLAG-<italic>GNAO1<sup>R243H</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>pRetroX-IRES-ZsGreen1 (empty vector)</p></list-item></list></p></list-item><list-item><p>Incubate for 30 min at room temperature.</p></list-item><list-item><p>Add DNA-Opti-MEM mixture to 500 µl Lipofectamine 2000.</p></list-item><list-item><p>Add DNA-Lipofectamine LTX complex to wells containing Phoenix cells and mix gently</p></list-item><list-item><p>Incubate cells for 18–48 hr.<list list-type="roman-lower"><list-item><p>Change media after 4–6 hr to complete media containing serum.</p></list-item></list></p></list-item><list-item><p>Harvest virus-containing supernatants 48 hr post transfection and re-feed cells with DMEM. Incubate at 37°C in a humidified 5% CO<sub>2</sub> incubator. Note: Multiple rounds of collection may be required for concentrating stock.<list list-type="roman-lower"><list-item><p>This initial collected media can be stored briefly at 4°C.</p></list-item></list></p></list-item><list-item><p>After an additional 12–24 hr of culture, collect viral supernatants again and pool with first collection.</p></list-item><list-item><p><sup>#</sup>Concentrate viral stock.<list list-type="roman-lower"><list-item><p>Centrifuge the viral supernatant at 3000 rpm for 15 min to remove any cell debris.</p></list-item><list-item><p>Filter the supernatant through a 0.45 µm syringe filter.</p></list-item><list-item><p>Ultracentrifuge at 22,000 rpm for 2 hr at 4°C to produce concentrated viral stocks.</p></list-item><list-item><p>Aliquot virus into screw-cap centrifuge tubes and store at -70°C.</p></list-item></list></p></list-item><list-item><p><sup>#</sup>Titre retrovirus<list list-type="roman-lower"><list-item><p>One day before harvesting viral supernatant, plate 1.2 × 10<sup>5</sup> HMECs per well of a 6 well dish.</p></list-item><list-item><p>On the day of viral supernatant harvesting, count the number of cells in one well to determine cell number at time of infection.</p></list-item><list-item><p>Add a range of volumes between 2 to 5 µl of concentrated viral supernatant to the wells. Incubate for 72 hr.</p></list-item><list-item><p>Remove culture medium, wash the wells once with 2 ml PBS.</p></list-item><list-item><p>Add 0.5 ml of 0.25% trypsin EDTA</p></list-item><list-item><p>Incubate 5 min at 37°C.</p></list-item><list-item><p>Add 0.5 ml DMEM-10 or 15 (10–15% FBS).</p></list-item><list-item><p>Pipette up and down with 1 ml pipette and transfer cells to a FACS tube.</p></list-item><list-item><p>Determine the percentage of GFP-positive cells by FACS analysis.</p></list-item><list-item><p>Calculate the number of transfection units (TU/ml):<list list-type="order"><list-item><p>Divide the % GFP-positive cells by 100.</p></list-item><list-item><p>Multiply that by the number of cells at the time of infection</p></list-item><list-item><p>Divide that number by the volume of the virus added (ml)</p></list-item><list-item><p>This will yield the number of viral particles per ml.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Use resulting virus to transduce HMECs in Step 3.</p></list-item></list></p></list-item><list-item><p><sup>#</sup>One day prior to transduction, seed HMECs in 15 cm plates so they will be 70–90% confluent on the day of transfection.</p></list-item><list-item><p><sup>#</sup>Transduce HMECs with the appropriate viruses (Optimal MOI will be determined prior to transduction).<list list-type="order"><list-item><p>Infect HMECs on a 24-well plate with lentivirus.<list list-type="roman-lower"><list-item><p>Cohort 1: Uninfected HMECs [additional negative control]</p></list-item><list-item><p>Cohort 2: HMECs transduced with pRETRO-IRES-ZsGreen1-empty vector [additional negative control]</p></list-item><list-item><p>Cohort 3: HMECs transduced with pRETRO-FLAG-<italic>GNAO1<sup>WT</sup></italic>-IRES- ZsGreen1</p></list-item><list-item><p>Cohort 4: HMECs transduced with pRETRO-FLAG-<italic>GNAO1 <sup>R243H</sup></italic>-IRES- ZsGreen1</p></list-item></list></p></list-item><list-item><p>After 72 hr, check cells under fluorescence microscope to calculate infection rate.</p></list-item></list></p></list-item><list-item><p><sup>#</sup>Sterile sort the top 10% of the transduced HMECs by <sup>#</sup>flow cytometry based on GFP expression.<list list-type="alpha-lower"><list-item><p>Trypsinize the cells and resuspend in PBS with 0.5% FBS (FACS buffer)</p></list-item><list-item><p>Pass the cells through the cell strainer to make a single cell suspension.</p></list-item><list-item><p>Sort cells for GFP signal (top 10% selected) on FACS sorter (Influx 100 μm-18 psi)<list list-type="roman-lower"><list-item><p>100,000 cells are collected per tube.</p></list-item></list></p></list-item></list></p></list-item><list-item><p><sup>#</sup>Perform Western blots on top 10% GFP positive HMECs to confirm expression of GNAO1:<list list-type="alpha-lower"><list-item><p>Spin down the cells for 5 min at maximum speed using an eppendorf tube centrifuge. Aspirate and discard the supernatant.</p></list-item><list-item><p>Add 100 µl to 200 µl of protein lysis buffer depending on the size of the cell pellet.<list list-type="roman-lower"><list-item><p><sup>#</sup>Protein lysis buffer: 4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl pH 6.8</p></list-item><list-item><p>Quantify protein concentration using a <sup>#</sup>Bradford assay according to manufacturer’s instructions.</p></list-item></list></p></list-item><list-item><p>Load equal amounts of total protein in 25 µl sample on a <sup>#</sup>12% SDS-PAGE gel.<list list-type="roman-lower"><list-item><p>Boil for 7 min before loading</p></list-item><list-item><p>Load one lane with 8 µl protein marker ladder.</p></list-item><list-item><p>Run at 150V for 10–15 min.</p></list-item><list-item><p>When samples reach separation gel, turn to 100V and run for approximately 1.5 hr. Record running time.</p></list-item></list></p></list-item><list-item><p>Wet transfer to <sup>#</sup>PVDF membrane <sup>#</sup>at 95V for 70 min.</p></list-item><list-item><p><sup>#</sup>Block membrane with 3% skim milk in Tris-buffered saline (TBS) on shaker for 30 min</p></list-item><list-item><p>Incubate with the following primary antibodies for 1 hr at 37°C:<list list-type="roman-lower"><list-item><p>Mouse Anti-FLAG M2 (1:500 dilution)</p></list-item><list-item><p><sup>#</sup>Mouse Anti-ß-ACTIN (<sup>#</sup>1:1000 dilution)</p></list-item></list></p></list-item><list-item><p>Wash membrane 3 times in 1X TBS for 5 min each on shaker.</p></list-item><list-item><p>Incubate with anti-mouse HRP conjugated secondary antibody (<sup>#</sup>1:1000) for 1 hr on shaker at room temperature.</p></list-item><list-item><p>Remove membrane from secondary antibody and wash three times in 1X TBS for 5 min each.</p></list-item><list-item><p>Prepare ECL solution and incubate membrane.</p></list-item><list-item><p>Expose membrane to X-ray film, develop and scan.</p></list-item></list></p></list-item></list></sec><sec id="s2-2-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Data for viral titration</p></list-item><list-item><p>Flow cytometry data (for viral titration and sorting of transduced cells)</p></list-item><list-item><p>Protein determination assay data.</p></list-item><list-item><p>Figure 3F: Full scans of all films for each western blot with ladder.</p></list-item></list></p></list-item><list-item><p>Sample delivered for further analysis:<list list-type="bullet"><list-item><p>HMECs transduced with:<list list-type="bullet"><list-item><p>pRetroX-IRES-ZsGreen1 (empty vector)</p></list-item><list-item><p>pRetroX-FLAG-<italic>GNAO1<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>pRetroX-FLAG-<italic>GNAO1<sup>R243H</sup></italic>-IRES-ZsGreen1</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-2-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>None applicable.</p></list-item></list></sec><sec id="s2-2-6"><title>Known differences from the original study</title><p>All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-2-7"><title>Provisions for quality control</title><p>The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. GNAO1 expression will be confirmed in the top 10% GFP positive HMECs with western blots. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/jpeqg/">https://osf.io/jpeqg/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-3"><title>Protocol 3: Anchorage-independent colony formation assay of HMECs transduced with wild-type or mutant GNAO1</title><p>This experiment tests the effect of WT or mutant GNAO1 expression on anchorage-independent colony formation of HMECs. It is a replication of the experiments reported in Figure 3D–E.</p><sec id="s2-3-1"><title>Sampling</title><list list-type="bullet"><list-item><p>Experiment to be repeated a total of 3 times for a power of 99%.<list list-type="bullet"><list-item><p>See Power Calculations section for details.</p></list-item></list></p></list-item><list-item><p>Experiment has 4 cohorts:<list list-type="bullet"><list-item><p>Cohort 1: Uninfected HMECs [additional negative control]</p></list-item><list-item><p>Cohort 2: HMECs transduced with pRetroX-IRES-ZsGreen1-empty vector [additional negative control]</p></list-item><list-item><p>Cohort 3: HMECs transduced with pRetroX-FLAG-<italic>GNAO1<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>Cohort 4: HMECs transduced with pRetroX-FLAG-<italic>GNAO1<sup>R243H</sup></italic>-IRES-ZsGreen1</p></list-item></list></p></list-item><list-item><p>Each cohort will have anchorage independent colony formation quantified.</p></list-item></list></sec><sec id="s2-3-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>HMECs</td><td>Cell line</td><td>ATCC</td><td>PCS-600-010</td><td>Original product number not specified; <break/>Replaces Life Technology brand used <break/>in original study</td></tr><tr><td>HMECs transduced with <break/>pRetroX-IRES-ZsGreen1-empty vector</td><td>Cell line</td><td colspan="3">Produced in Protocol 2</td></tr><tr><td>HMECs transduced with <break/>pRetroX-FLAG-<italic>GNAO1<sup>WT</sup></italic>-IRES-ZsGreen1</td><td>Cell line</td><td colspan="3">Produced in Protocol 2</td></tr><tr><td>HMECs transduced with <break/>pRetroX-FLAG-<italic>GNAO1 <sup>R243H</sup></italic>-IRES-ZsGreen1</td><td>Cell line</td><td colspan="3">Produced in Protocol 2</td></tr><tr><td>HMEC medium</td><td>Cell culture</td><td>ATCC</td><td>PCS-600-03</td><td>Replaces Life Technology brand <break/>used in original study</td></tr><tr><td>HMEC supplement</td><td>Cell culture</td><td>ATCC</td><td>PCS-600-040</td><td>Original product number not specified; <break/>Replaces Life Technology brand used <break/>in original study</td></tr><tr><td>Bovine pituitary extract</td><td>Cell culture</td><td>Life Technologies</td><td>13028014</td><td>Originl not specified</td></tr><tr><td>Penicillin/streptomycin</td><td>Cell culture</td><td>ABM</td><td>G255</td><td>Original not specified</td></tr><tr><td>6 well plates</td><td>Labware</td><td>Fisher Scientific</td><td>Biolite 12556004</td><td>Original not specified</td></tr><tr><td>Low melting temperature agar</td><td>Cell culture</td><td>Bioworld</td><td>40100048-2</td><td>Original not specified</td></tr><tr><td>Crystal violet</td><td>Dye</td><td colspan="2" rowspan="3">Left to the discretion of the replicating lab</td><td rowspan="3">Not originally used</td></tr><tr><td>Methanol (MeOH)</td><td>Chemical</td></tr><tr><td>Acetic acid</td><td>Chemical</td></tr><tr><td>ImageJ</td><td>Software</td><td>NIH</td><td/><td>Replaces Oxford Optronix GelCount <break/>imager and software</td></tr></tbody></table></table-wrap></sec><sec id="s2-3-3"><title>Procedure</title><p>Notes:</p><list list-type="bullet"><list-item><p>Transduced HMECs are generated in Protocol 2.</p></list-item></list><list list-type="order"><list-item><p>Grow 3 flasks of transduced and untransduced control HMECs in complete HMEC medium: HMEC medium supplemented with HMEC supplement, <sup>#</sup>0.5 mg/mL bovine pituitary extract, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO<sub>2</sub> (these will be the biological replicates).</p></list-item><list-item><p>Plate a lower layer of <sup>#</sup>1 ml 0.5% agar per well in twelve wells of 6-well plates.<list list-type="alpha-lower"><list-item><p>Let solidify.</p></list-item></list></p></list-item><list-item><p>Suspend 3 wells each of 3 × 10<sup>4</sup> HMECs in 1 ml full media containing 0.35% agar containing either:<list list-type="alpha-lower"><list-item><p>untransduced HMECs</p></list-item><list-item><p>HMECs transduced with pRetroX-IRES-ZsGreen1 (empty vector)</p></list-item><list-item><p>HMECs transduced with pRetroX-FLAG-<italic>GNAO1<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>HMECs transduced with pRetroX-FLAG-<italic>GNAO1<sup>R243H</sup></italic>-IRES-ZsGreen1</p></list-item></list></p></list-item><list-item><p>Plate <sup>#</sup>1 ml suspended cells on top of the lower layer of 0.5% agar in 6-well plates.</p></list-item><list-item><p>Incubate the plates for 3 weeks at 37°C and 5% CO<sub>2</sub>.<list list-type="alpha-lower"><list-item><p><sup>#</sup>Refresh growth media on top layer every 2–3 days.</p></list-item></list></p></list-item><list-item><p>Assess the presence of colonies.<list list-type="alpha-lower"><list-item><p>Stain wells with crystal violet.<list list-type="order"><list-item><p>Remove media from wells.</p></list-item><list-item><p>Fix with 500 µl of 10% MeOH/10% acetic acid for 10 min.</p></list-item><list-item><p>Remove and stain with 500 µl 0.01% crystal violet for 1 hr.</p></list-item><list-item><p>Remove stain and wash wells.</p></list-item></list></p></list-item><list-item><p>Image entire well with high-resolution camera.<list list-type="order"><list-item><p>Include calibration scale in image.</p></list-item></list></p></list-item><list-item><p>Quantify the number of colonies greater than 200 µm in diameter using ImageJ software.<list list-type="order"><list-item><p>Set threshold using calibration scale taken during image acquisition.</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-3-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Figure 3D: Images of colonies.</p></list-item><list-item><p>Raw numbers for quantification of colonies for each sample.</p></list-item><list-item><p>Figure 3E: Graph of mean number of colonies for each cohort.</p></list-item></list></p></list-item></list></sec><sec id="s2-3-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data:</p></list-item><list-item><p>Note: At the time of analysis we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.<list list-type="bullet"><list-item><p>Unpaired two-tailed <italic>t</italic>-test of the mean number of colonies in HMECs expressing exogenous GNAO1<sup>WT</sup> or GNAO1<sup>R243H</sup>.</p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot</p></list-item></list></p></list-item></list></sec><sec id="s2-3-6"><title>Known differences from the original study</title><p>The original study counted cell colonies using GelCount to image, count, and analyze colonies, while the replication attempt will stain with crystal violet to enhance detection of cell colonies, image wells with a high-resolution camera, and use ImageJ software to count and analyze colonies. Since the software and approach used by the original and replication attempt are different, there will likely be some differences in sensitivity and error rates. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-3-7"><title>Provisions for quality control</title><p>The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/jpeqg/">https://osf.io/jpeqg/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-4"><title>Protocol 4: Generation of NIH3T3 cells stably expressing wild-type or mutant MAP2K4</title><p>This protocol describes the generation of NIH3T3 cells stably expressing wild-type or mutant MAP2K4 proteins. This protocol also describes verification of expression of MAP2K4 by western blot that will be a replication of Figure 4E. These cells will subsequently be used in Protocols 4 and 5.</p><sec id="s2-4-1"><title>Sampling</title><list list-type="bullet"><list-item><p>This experiment will be conducted one time to confirm stable expression of exogenous MAP2K4.</p></list-item><list-item><p>Experiment has 5 cohorts:<list list-type="bullet"><list-item><p>Cohort 1: Uninfected NIH3T3 cells [additional negative control]</p></list-item><list-item><p>Cohort 2: transduced with pRetroX-IRES-ZsGreen1 (empty vector)</p></list-item><list-item><p>Cohort 3: transduced with pRetroX-FLAG-<italic>MAP2K4<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>Cohort 4: transduced with pRetroX-FLAG-<italic>MAP2K4<sup>R228K</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>Cohort 5: transduced with pRetroX-FLAG-<italic>MAP2K4<sup>A279T</sup></italic>-IRES-ZsGreen1</p></list-item></list></p></list-item><list-item><p>To confirm MAP2K4 expression, Western blotting will be performed for the following proteins:<list list-type="bullet"><list-item><p>FLAG</p></list-item><list-item><p>β-ACTIN [Additional loading control]</p></list-item></list></p></list-item></list></sec><sec id="s2-4-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>NIH3T3 cells</td><td>Cell line</td><td>ATCC</td><td>CRL-1658</td><td/></tr><tr><td>DMEM medium</td><td>Cell culture</td><td>Sigma</td><td>11965-092</td><td>Original not specified</td></tr><tr><td>FBS</td><td>Cell culture</td><td>Life Technologies</td><td>12483-020</td><td>Original not specified</td></tr><tr><td>L-glutamine</td><td>Cell culture</td><td>Life Technologies</td><td>35050-061</td><td>Original not specified</td></tr><tr><td>Penicillin/Streptomycin</td><td>Cell culture</td><td>Applied Biological Materials</td><td>G255</td><td>Original not specified</td></tr><tr><td>pRetroX-IRES-ZsGreen1 vector</td><td>Plasmid</td><td colspan="3">Produced in Protocol 1</td></tr><tr><td>pRetroX-FLAG-<italic>MAP2K4<sup>WT</sup></italic>- <break/>IRES-ZsGreen1 vector</td><td>Plasmid</td><td colspan="3">Produced in Protocol 1</td></tr><tr><td>pRetroX-FLAG-<italic>MAP2K4<sup>R228K</sup></italic>- <break/>IRES-ZsGreen1 vector</td><td>Plasmid</td><td colspan="3">Produced in Protocol 1</td></tr><tr><td>pRetroX-FLAG-<italic>MAP2K4<sup>A279T</sup></italic>- <break/>IRES-ZsGreen1 vector</td><td>Plasmid</td><td colspan="3">Produced in Protocol 1</td></tr><tr><td>Phoenix amphoteric cells</td><td>Cell line</td><td>ATCC</td><td>ATCC CRL-3213</td><td>Replaces Orbigen <break/>brand used in original study</td></tr><tr><td>Lipofectamine 2000</td><td>Transfection Reagent</td><td>Life Technologies</td><td>11668027</td><td/></tr><tr><td>Opti-MEM</td><td>Transfection Reagent</td><td>Sigma-Aldrich</td><td>31985070</td><td>Original not specified</td></tr><tr><td>PBS</td><td>Buffer</td><td>GIBCO</td><td>10010023</td><td>Original not specified</td></tr><tr><td>0.45 µm syringe filter</td><td>Labware</td><td>Millipore</td><td>SLHV033RB</td><td>Original not specified</td></tr><tr><td>Trypsin EDTA</td><td>Buffer</td><td>ABM</td><td>TM050</td><td>Original not specified</td></tr><tr><td>FBS</td><td>Buffer</td><td>GIBCO</td><td>12483</td><td>Original not specified</td></tr><tr><td>SDS</td><td>Chemical</td><td/><td/><td/></tr><tr><td>2-mercaptoethanol</td><td>Chemical</td><td/><td/><td/></tr><tr><td>Glycerol</td><td>Chemical</td><td/><td/><td/></tr><tr><td>bromophenol blue</td><td>Chemical</td><td/><td/><td/></tr><tr><td>Tris-HCl</td><td>Chemical</td><td/><td/><td/></tr><tr><td>Bradford Assay</td><td>Detection assay</td><td>Sigma</td><td>B6916-500 ML</td><td>Original not specified</td></tr><tr><td>12% SDS-PAGE gel</td><td>Western Blot Reagent</td><td>Invitrogen</td><td>EC60252BOX</td><td>Original 4–20%</td></tr><tr><td>OptiProtein Marker</td><td>Western Blot Reagent</td><td>Applied Biological Materials</td><td>G252</td><td>Original not specified</td></tr><tr><td>PVDF membrane</td><td>Western Blot Reagent</td><td>Biorad</td><td>162-0015</td><td>Original Nitrocellulose</td></tr><tr><td>1X TBS solution</td><td>Buffer</td><td>Fisher Scientific</td><td>BP2471-100</td><td>Original not specified</td></tr><tr><td>Anti-FLAG M2 antibody</td><td>Antibody</td><td>Sigma</td><td>F1804</td><td/></tr><tr><td>Anti-ß-ACTIN antibody</td><td>Antibody</td><td>Abcam</td><td>Ab8227</td><td>Original not specified</td></tr><tr><td>Anti-mouse HRP-conjugated <break/>secondary antibody</td><td>Antibody</td><td>Abcam</td><td>Ab6728</td><td>Original not specified</td></tr><tr><td>ECL Reagent A and B</td><td>Western Blot Reagent</td><td>Applied Biological Materials</td><td>G075</td><td>Replaces Thermo Fisher brand.</td></tr><tr><td>X-ray Film</td><td>Western Blot Reagent</td><td>Kodak</td><td>XBT-1</td><td>Original not specified</td></tr></tbody></table></table-wrap></sec><sec id="s2-4-3"><title>Procedure</title><p>Notes:</p><list list-type="bullet"><list-item><p>NIH3T3 cells are grown in complete DMEM medium: DMEM medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO<sub>2</sub>.</p></list-item><list-item><p>Phoenix cells grown in complete DMEM medium: DMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO<sub>2</sub>.</p></list-item><list-item><p>All cells will be sent for mycoplasma testing and STR profiling.</p></list-item></list><list list-type="order"><list-item><p>Transfect Phoenix cells with the appropriate constructs as in Protocol 2 step 1.</p></list-item><list-item><p>Transduce NIH3T3 cells with the appropriate viruses as in Protocol 2 steps 2 and</p></list-item><list-item><p>Sterile sort the top 10% of the transduced NIH3T3 cells by flow cytometry based on GFP expression as in Protocol 2 Step 4.</p></list-item><list-item><p>Perform western blot on sorted cells to confirm expression of MAP2K4 as in Protocol 2 Step 5.</p></list-item></list></sec><sec id="s2-4-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Data for viral titration</p></list-item><list-item><p>Flow cytometry data (for viral titration and sorting of transduced cells)</p></list-item><list-item><p>Protein determination assay data.</p></list-item><list-item><p>Figure 4E: Full scans of all films for each western with ladder.</p></list-item></list></p></list-item><list-item><p>Sample delivered for further analysis:<list list-type="bullet"><list-item><p>NIH3T3 cells transduced with:<list list-type="bullet"><list-item><p>pRetroX-IRES-ZsGreen1 (empty vector)</p></list-item><list-item><p>pRetroX-FLAG-<italic>MAP2K4<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>pRetroX-FLAG-<italic>MAP2K4<sup>R228K</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>pRetroX-FLAG-<italic>MAP2K4<sup>A279T</sup></italic>-IRES-ZsGreen1</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-4-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>None applicable.</p></list-item></list></sec><sec id="s2-4-6"><title>Known differences from the original study</title><p>Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-4-7"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. MAP2K4 expression will be confirmed in the top 10% GFP positive HMECs with Western blots. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/jpeqg/">https://osf.io/jpeqg/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-5"><title>Protocol 5: Anchorage-independent colony formation assay of NIH3T3 cells transduced with wild-type or mutant MAP2K4</title><p>This experiment tests the effect of WT or mutant MAP2K4 expression on anchorage-independent colony formation of NIH3T3 cells. It is a replication of the experiments reported in Figure 4C and 4D.</p><sec id="s2-5-1"><title>Sampling</title><list list-type="bullet"><list-item><p>Experiment to be repeated a total of 3 times for a minimum power of 99%.<list list-type="bullet"><list-item><p>See Power Calculations section for details.</p></list-item></list></p></list-item><list-item><p>Experiment has 5 (generated in Protocol 4) cohorts:<list list-type="bullet"><list-item><p>Cohort 1: Uninfected NIH3T3 cells [additional negative control]</p></list-item><list-item><p>Cohort 2: NIH3T3 cells transduced with with pRetroX-IRES-ZsGreen1-empty vector</p></list-item><list-item><p>Cohort 3: NIH3T3 cells transduced with with pRetroX-FLAG-<italic>MAP2K4<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>Cohort 4: NIH3T3 cells transduced with with pRetroX-FLAG-<italic>MAP2K4<sup>R228K</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>Cohort 5: NIH3T3 cells transduced with with pRetroX-FLAG-<italic>MAP2K4<sup>A279T</sup></italic>-IRES-ZsGreen1</p></list-item></list></p></list-item><list-item><p>Each cohort will have anchorage independent colony formation quantified.</p></list-item></list></sec><sec id="s2-5-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>NIH3T3 cells transduced with <break/>pRetroX-IRES-ZsGreen1-empty vector</td><td>Cell line</td><td colspan="3">Produced in Protocol 4</td></tr><tr><td>NIH3T3 cells transduced with <break/>pRetroX-FLAG-<italic>MAP2K4<sup>WT</sup></italic>-IRES-ZsGreen1</td><td>Cell line</td><td colspan="3">Produced in Protocol 4</td></tr><tr><td>NIH3T3 cells transduced with <break/>pRetroX-FLAG-<italic>MAP2K4<sup>R228K</sup></italic>-IRES-ZsGreen1</td><td>Cell line</td><td colspan="3">Produced in Protocol 4</td></tr><tr><td>NIH3T3 cells transduced with <break/>pRetroX-FLAG-<italic>MAP2K4<sup>A279T</sup></italic>-IRES-ZsGreen1</td><td>Cell line</td><td colspan="3">Produced in Protocol 4</td></tr><tr><td>DMEM medium</td><td>Cell culture</td><td>Sigma</td><td>11965-092</td><td>Original not specified</td></tr><tr><td>FBS</td><td>Cell culture</td><td>Life Technologies</td><td>12483-020</td><td>Original not specified</td></tr><tr><td>L-glutamine</td><td>Cell culture</td><td>Life Technologies</td><td>35050-061</td><td>Original not specified</td></tr><tr><td>Penicillin/streptomycin</td><td>Cell culture</td><td>Applied Biological Materials</td><td>G255</td><td>Original not specified</td></tr><tr><td>6 well plates</td><td>Labware</td><td>Fisher Scientific</td><td>Biolite 12556004</td><td>Original not specified</td></tr><tr><td>Low melting temperature agar</td><td>Cell culture</td><td>Bioworld</td><td>40100048-2</td><td>Original not specified</td></tr><tr><td>Crystal violet</td><td>Dye</td><td colspan="2" rowspan="3">Left to the discretion of the replicating lab <break/></td><td rowspan="3">Not originally used</td></tr><tr><td>Methanol (MeOH)</td><td>Chemical</td></tr><tr><td>Acetic acid</td><td>Chemical</td></tr><tr><td>ImageJ</td><td>Software</td><td>NIH</td><td/><td>Replaces Oxford Optronix GelCount <break/>imager and software</td></tr></tbody></table></table-wrap></sec><sec id="s2-5-3"><title>Procedure</title><p>Note:</p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and STR profiling.</p></list-item></list><list list-type="order"><list-item><p>Grow 3 flasks each of transduced NIH3T3 cells generated in Protocol 4 in complete DMEM medium: DMEM medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO<sub>2</sub>. (these will be the biological replicates)</p></list-item><list-item><p>Plate a lower layer of <sup>#</sup>1 ml 0.5% agar per well in 16 wells of 6-well plates.<list list-type="alpha-lower"><list-item><p>Let solidify.</p></list-item></list></p></list-item><list-item><p>Suspend 3 plates each of 1 × 10<sup>4</sup> cells/plate in 1 ml full media containing 0.35% agar containing either:<list list-type="bullet"><list-item><p>uninfected NIH3T3 cells [additional negative control]</p></list-item><list-item><p>NIH3T3 cells transduced with pRetroX-IRES-ZsGreen1-empty vector</p></list-item><list-item><p>NIH3T3 cells transduced with pRetroX-FLAG-<italic>MAP2K4<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>NIH3T3 cells transduced with pRetroX-FLAG-<italic>MAP2K4<sup>R228K</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>NIH3T3 cells transduced with pRetroX-FLAG-<italic>MAP2K4<sup>A279T</sup></italic>-IRES-ZsGreen1</p></list-item></list></p></list-item><list-item><p>Plate <sup>#</sup>1 ml suspended cells on top of the lower layer of 0.5% agar in 6-well plates.</p></list-item><list-item><p>Incubate the plates for 3 weeks at 37°C and 5% CO<sub>2</sub>.<list list-type="alpha-lower"><list-item><p><sup>#</sup>Refresh growth media from top layer every 2–3 days.</p></list-item></list></p></list-item><list-item><p>Assess the presence of colonies.<list list-type="alpha-lower"><list-item><p>Stain wells with crystal violet.<list list-type="order"><list-item><p>Remove media from wells.</p></list-item><list-item><p>Fix with 500 µl of 10% MeOH/10% acetic acid for 10 min.</p></list-item><list-item><p>Remove and stain with 500 µl 0.01% crystal violet for 1 hr.</p></list-item><list-item><p>Remove stain and wash wells.</p></list-item></list></p></list-item><list-item><p>Image entire well with a high-resolution camera.<list list-type="order"><list-item><p>Include calibration scale in image.</p></list-item></list></p></list-item><list-item><p>Quantify the number of colonies greater than 100 µm in diameter using ImageJ software.<list list-type="order"><list-item><p>Set threshold using scale taken during image acquisition.</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-5-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Figure 4C: Images of colonies.</p></list-item><list-item><p>Raw numbers for quantification of colonies for each sample.</p></list-item><list-item><p>Figure 4D: Graph of mean number of colonies for each cohort.</p></list-item></list></p></list-item></list></sec><sec id="s2-5-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data:</p></list-item><list-item><p>Note: At the time of analysis we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.<list list-type="bullet"><list-item><p>One-way ANOVA of the mean number of colonies in NIH3T3 cells expressing exogenous MAP2K4<sup>WT</sup>, MAP2K4<sup>R228K</sup>, or MAP2K4<sup>A279T</sup> followed by planned comparisons using Fisher’s LSD:<list list-type="bullet"><list-item><p>MAP2K4<sup>WT</sup> vs MAP2K4<sup>R228K</sup></p></list-item><list-item><p>MAP2K4<sup>WT</sup> vs MAP2K4<sup>A279T</sup></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></p></list-item></list></sec><sec id="s2-5-6"><title>Known differences from the original study</title><p>Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. The original study counted cell colonies using GelCount to image, count, and analyze colonies, while the replication attempt will stain with crystal violet to enhance detection of cell colonies, image wells with a high-resolution camera, and use ImageJ software to count and analyze colonies. Since the software and approach used by the original and replication attempt are different, there will likely be some differences in sensitivity and error rates. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-5-7"><title>Provisions for quality control</title><p>The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/jpeqg/">https://osf.io/jpeqg/</ext-link>) and made publically available.</p></sec></sec><sec id="s2-6"><title>Protocol 6: Assessing the kinase activity of wild-type or mutant MAP2K4</title><p>This experiment tests the <italic>in vitro</italic> kinase activity of WT or mutant MAP2K4 immunoprecipitated from NIH3T3 cells. It is a replication of the experiment reported in Figure 4F.</p><sec id="s2-6-1"><title>Sampling</title><list list-type="bullet"><list-item><p>Experiment to be repeated a total of 4 times.<list list-type="bullet"><list-item><p>The original data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes were determined based on a range of potential variance.<list list-type="bullet"><list-item><p>See Power Calculations section for details.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Experiment has 5 cohorts:<list list-type="bullet"><list-item><p>Cohort 1: Uninfected NIH3T3 cells [additional negative control]</p></list-item><list-item><p>Cohort 2: NIH3T3 cells transduced with pRetroX-IRES-ZsGreen1 (empty vector)</p></list-item><list-item><p>Cohort 3: NIH3T3 cells transduced with pRetroX-FLAG-<italic>MAP2K4<sup>WT</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>Cohort 4: NIH3T3 cells transduced pRetroX-FLAG-<italic>MAP2K4<sup>R228K</sup></italic>-IRES-ZsGreen1</p></list-item><list-item><p>Cohort 5: NIH3T3 cells transduced with pRetroX-FLAG-<italic>MAP2K4<sup>A279T</sup></italic>-IRES-ZsGreen1</p></list-item></list></p></list-item><list-item><p>A kinase assay is performed for each cohort using the following substrates:<list list-type="bullet"><list-item><p>Myelin basic protein (MBP)</p></list-item><list-item><p>Inactive MAPK9/JNK2</p></list-item></list></p></list-item></list></sec><sec id="s2-6-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>NIH3T3 cells transduced with <break/>pRetroX-IRES-ZsGreen1-empty vector</td><td>Cell line</td><td colspan="3">Produced in Protocol 4</td></tr><tr><td>NIH3T3 cells transduced with <break/>pRetroX-FLAG-<italic>MAP2K4<sup>WT</sup></italic>- <break/>IRES-ZsGreen1</td><td>Cell line</td><td colspan="3">Produced in Protocol 4</td></tr><tr><td>NIH3T3 cells transduced with <break/>pRetroX-FLAG-<italic>MAP2K4<sup>R228K</sup></italic>- <break/>IRES-ZsGreen1</td><td>Cell line</td><td colspan="3">Produced in Protocol 4</td></tr><tr><td>NIH3T3 cells transduced with <break/>pRetroX-FLAG-<italic>MAP2K4<sup>A279T</sup></italic>- <break/>IRES-ZsGreen1</td><td>Cell line</td><td colspan="3">Produced in Protocol 4</td></tr><tr><td>DMEM medium</td><td>Cell culture</td><td>Sigma</td><td>11965-092</td><td>Original not specified</td></tr><tr><td>FBS</td><td>Cell culture</td><td>Life Technologies</td><td>12483-020</td><td>Original not specified</td></tr><tr><td>L-glutamine</td><td>Cell culture</td><td>Life Technologies</td><td>35050-061</td><td>Original not specified</td></tr><tr><td>EZview FLAG-M2-antibody-coupled <break/>affinity gel</td><td>Chromatography</td><td>Sigma</td><td>A2220</td><td/></tr><tr><td>Penicillin/streptomycin</td><td>Cell culture</td><td>Applied Biological Materials</td><td>G255</td><td>Original not specified</td></tr><tr><td>Cell Lysis Buffer</td><td>Buffer</td><td>Cell Signaling Technology</td><td>9803</td><td>Original product number <break/>not specified</td></tr><tr><td>Phenylmethanesulfonyl <break/>Fluoride (PMSF)</td><td>Protease inhibitor</td><td>Cell Signaling Technology</td><td>8853</td><td>Original not specified</td></tr><tr><td>Myelin basic protein</td><td>Protein</td><td>Signalchem</td><td>M42-51N</td><td>Replaces Millipore AB15542</td></tr><tr><td>Inactive MAPK9/JNK2</td><td>Protein</td><td>Invitrogen</td><td>PV3621</td><td>Listed as MAP2K7 in <break/>original paper.</td></tr><tr><td>[γ-32P]ATP</td><td>Chemical</td><td>Perkin Elmer</td><td>BLU002H250UC</td><td/></tr><tr><td>Kinase Reaction Buffer</td><td>Buffer</td><td>Cell Signaling Technology</td><td>9802</td><td>Original product number <break/>not specified</td></tr><tr><td>Anti-FLAG M2 Magnetic Beads</td><td>Kinase assay reagent</td><td>Sigma-Aldrich</td><td>M8823</td><td>Original not specified</td></tr><tr><td>12% SDS-PAGE</td><td>Western Blot Reagent</td><td>Invitrogen</td><td>EC60252BOX</td><td>Original 4–20%</td></tr><tr><td>Bradford Assay</td><td>Detection assay</td><td>Sigma</td><td>B6916-500 ML</td><td>Original not specified</td></tr><tr><td>OptiProtein Marker</td><td>Western Blot Reagent</td><td>Applied Biological Materials</td><td>G252</td><td>Original not specified</td></tr><tr><td>PVDF membrane</td><td>Western Blot Reagent</td><td>Biorad</td><td>162-0015</td><td>Original Nitrocellulose</td></tr><tr><td>Skim milk powder</td><td>Western Blot Reagent</td><td>Fisher Scientific</td><td>361021617</td><td>Original not specified</td></tr><tr><td>1X TBS solution</td><td>Buffer</td><td>Fisher Scientific</td><td>BP2471-100</td><td>Original not specified</td></tr><tr><td>Anti-FLAG M2 antibody</td><td>Antibody</td><td>Sigma</td><td>F1804</td><td/></tr><tr><td>Anti-ß-ACTIN antibody</td><td>Antibody</td><td>Abcam</td><td>Ab8227</td><td>Original not specified</td></tr><tr><td>Anti-mouse HRP-conjugated <break/>secondary antibody</td><td>Antibody</td><td>Abcam</td><td>Ab6728</td><td>Original not specified</td></tr><tr><td>ECL Reagent A and B</td><td>Western Blot Reagent</td><td>Applied Biological Materials</td><td>G075</td><td>Replaces Thermo <break/>Fisher brand.</td></tr><tr><td>X-ray Film</td><td>Western Blot Reagent</td><td>Kodak</td><td>XBT-1</td><td>Original not specified</td></tr></tbody></table></table-wrap></sec><sec id="s2-6-3"><title>Procedure</title><p>Note:</p><list list-type="bullet"><list-item><p>Transduced NIH3T3 cells are generated in Protocol 4.</p></list-item><list-item><p>All cells will be sent for mycoplasma testing and STR profiling.</p></list-item></list><list list-type="order"><list-item><p>Grow 4 flasks of NIH3T3 in complete DMEM medium: DMEM medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin cultured at 37°C and 5% CO<sub>2</sub>. These are the biological replicates.</p></list-item><list-item><p>Generate cell lysates:<list list-type="alpha-lower"><list-item><p>Plate cells for kinase assay so they will be 70–90% confluent on the day of harvest.</p></list-item><list-item><p>Replace with serum free media (0% FBS) and serum starve cells for 24 hr.</p></list-item><list-item><p>Wash cells with PBS and lyse with Cell Lysis Buffer (with 1 mM PMSF added just before use).</p></list-item><list-item><p>Clarify lysates.</p></list-item><list-item><p>Quantify protein concentration using a Bradford Assay according to manufacturer’s instructions.</p></list-item><list-item><p>Adjust samples to equalize for total amount of protein and concentration.</p></list-item></list></p></list-item><list-item><p>Perform immunoprecipitation:<list list-type="alpha-lower"><list-item><p>Incubate clarified lysates with anti-FLAG-M2 conjugated beads overnight at 4°C.</p></list-item><list-item><p>Spin beads down at 10,000x<italic>g</italic> for 30 s, remove supernatant and wash three times with Cell lysis buffer (with 1 mM PMSF added just before use).</p></list-item><list-item><p>Remove sample for input analysis and divide sample equally between two microcentrifuge tubes.</p></list-item><list-item><p>Spin beads down and remove supernatant.</p></list-item></list></p></list-item><list-item><p>Kinase Assay<list list-type="alpha-lower"><list-item><p>Add 25 µl of Kinase Reaction Buffer supplemented with 10 µM ATP and 2 µCi [γ-32P]ATP with either:<list list-type="roman-lower"><list-item><p>Myelin basic protein (MBP) (<sup>#</sup>1:2000)</p></list-item><list-item><p>Inactive MAPK9/JNK2 (<sup>#</sup>1:2000).</p></list-item></list></p></list-item><list-item><p>Incubate samples for 30 min at 30°C.</p></list-item><list-item><p>Stop kinase reactions by adding SDS sample buffer.</p></list-item><list-item><p>Resolve kinase reactions on <sup>#</sup>15% SDS-PAGE gel with protein ladder.</p></list-item><list-item><p><sup>#</sup>Fix gel for 15 min in 5% methanol, 7% acetic acid and dry at 60°C for 30 min.</p></list-item><list-item><p>Expose gel to X-ray film and scan images.</p></list-item></list></p></list-item><list-item><p>Perform western blot on input sample for MAP2K4 expression as in Protocol 2 Step 5.</p></list-item><list-item><p>For each replicate normalize each protein (MBP and MAPK9/JNK2) to MAP2K4 input levels and then normalize each sample to MAP2K4<sup>WT</sup>.</p></list-item></list></sec><sec id="s2-6-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Protein determination assay data.</p></list-item><list-item><p>Figure 4F: Full images of autoradiographs for each kinase assay substrate with ladder.</p></list-item><list-item><p>Figure 4F: Scans of full films for western blot of MAP2K4 input with ladder.</p></list-item></list></p></list-item></list></sec><sec id="s2-6-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data:</p></list-item><list-item><p>Note: At the time of analysis we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.<list list-type="bullet"><list-item><p>Bonferroni corrected one-sample <italic>t</italic>-tests of normalized pMBP levels from the following MAP2K4 variants compared to 1 (MAP2K4<sup>WT</sup>):<list list-type="bullet"><list-item><p>MAP2K4<sup>R228K</sup></p></list-item><list-item><p>MAP2K4<sup>A279T</sup></p></list-item></list></p></list-item><list-item><p>Bonferroni corrected one-sample <italic>t</italic>-tests of normalized pMAPK9/pJNK levels from the following MAP2K4 variants compared to 1 (MAP2K4<sup>WT</sup>):<list list-type="bullet"><list-item><p>MAP2K4<sup>R228K</sup></p></list-item><list-item><p>MAP2K4<sup>A279T</sup></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of effect sizes:<list list-type="bullet"><list-item><p>Since some of the band intensities in the original paper were unable to be quantified the replication study will record and make accessible all autoradiographs collected. This will allow for a subjective comparison of the original images and the replication images. Additionally, the replication will quantify the results in an additional exploratory measure. This cannot be compared to the original reported results, but will be presented to understand the utility of analyzing the data in a quantitative manner.</p></list-item></list></p></list-item></list></sec><sec id="s2-6-6"><title>Known differences from the original study</title><p>Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-6-7"><title>Provisions for quality control</title><p>The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/jpeqg/">https://osf.io/jpeqg/</ext-link>) and made publically available.</p></sec></sec></sec><sec id="s3"><title>Power calculations</title><p>For additional details on power calculations, please see analysis scripts and associated files on the Open Science Framework:</p><p><ext-link ext-link-type="uri" xlink:href="https://osf.io/bxr2d/">https://osf.io/bxr2d/</ext-link></p><sec id="s3-1"><title>Protocol 1:</title><list list-type="bullet"><list-item><p>Not applicable</p></list-item></list></sec><sec id="s3-2"><title>Protocol 2:</title><list list-type="bullet"><list-item><p>Not applicable</p></list-item></list></sec><sec id="s3-3"><title>Protocol 3:</title><sec id="s3-3-1"><title>Summary of original data</title><list list-type="bullet"><list-item><p>Note; values are from data shared by authors, which was reported in Figure 3E.</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Vector</th><th>Mean # of colonies &gt;200 μm diameter</th><th>Stdev</th><th>N</th></tr></thead><tbody><tr><td>WT</td><td>113.5</td><td>10.607</td><td>2</td></tr><tr><td>R243H</td><td>201.5</td><td>16.263</td><td>2</td></tr></tbody></table></table-wrap></sec><sec id="s3-3-2"><title>Test family</title><list list-type="bullet"><list-item><p>Two-tailed <italic>t</italic> test, difference between two independent means, alpha error = 0.050</p></list-item></list></sec><sec id="s3-3-3"><title>Power calculations</title><list list-type="bullet"><list-item><p>Performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib13">Faul et al., 2007</xref>).</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>WT</td><td>R243H</td><td>6.40954</td><td>87.2%<sup>1,2</sup></td><td>2<sup>1</sup></td><td>2<sup>1</sup></td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p><sup>1</sup> 3 samples per group will be used making the achieved power of 99.9%.</p></fn><fn id="tblfn3"><p><sup>2</sup> The calculation was also performed with the non-parametric Wilcoxon-Mann-Whitney test, which gives an achieved power of 99.9% with a sample size of 3 per group.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3-4"><title>Protocol 4:</title><list list-type="bullet"><list-item><p>Not applicable</p></list-item></list></sec><sec id="s3-5"><title>Protocol 5:</title><sec id="s3-5-1"><title>Summary of original data</title><list list-type="bullet"><list-item><p>Note: values are from data shared by authors, which was reported in Figure 4D:</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Vector</th><th>Mean # of colonies &gt;100 μm diameter</th><th>Stdev</th><th>N</th></tr></thead><tbody><tr><td>WT</td><td>16</td><td>2.8284</td><td>2</td></tr><tr><td>R228K</td><td>36</td><td>2.8284</td><td>2</td></tr><tr><td>A279T</td><td>94.5</td><td>7.7782</td><td>2</td></tr></tbody></table></table-wrap></sec><sec id="s3-5-2"><title>Test family</title><list list-type="bullet"><list-item><p>ANOVA: Fixed effects, omnibus, one-way, alpha error = 0.05</p></list-item></list></sec><sec id="s3-5-3"><title>Power calculations</title><list list-type="bullet"><list-item><p>Performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib13">Faul et al., 2007</xref>).</p></list-item><list-item><p>ANOVA F test statistic and partial η<sup>2</sup> performed with R software, version 3.1.2 (<xref ref-type="bibr" rid="bib41">Team, 2014</xref>).</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>F test statistic</th><th>Partial η<sup>2</sup></th><th>Effect size <italic>f</italic></th><th>A priori power</th><th>Total sample size</th></tr></thead><tbody><tr><td>NIH3T3 cells transduced with <break/>WT or <italic>MAP2K4</italic> mutants</td><td>F<sub>(2,3)</sub> = 130.52</td><td>0.98864</td><td>9.3280</td><td>99.9%</td><td>6<sup>1</sup> <break/>(3 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><p><sup>1</sup>9 total samples (3 per group) will be used as a minimum sample size making the power 99.9%.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-5-4"><title>Test family</title><list list-type="bullet"><list-item><p>Two-tailed <italic>t</italic> test, difference between two independent means, Fisher’s LSD: alpha error = 0.05</p></list-item></list></sec><sec id="s3-5-5"><title>Power calculations</title><list list-type="bullet"><list-item><p>Performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib13">Faul et al., 2007</xref>).</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>WT</td><td>R228K</td><td>7.07107</td><td>99.9%<sup>1,2</sup></td><td>2<sup>1</sup></td><td>2<sup>1</sup></td></tr><tr><td>WT</td><td>A279T</td><td>13.4134</td><td>99.9%<sup>1,2</sup></td><td>2<sup>1</sup></td><td>2<sup>1</sup></td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p><sup>1</sup> 3 samples per group will be used making the power 99.9%.</p></fn><fn id="tblfn6"><p><sup>2</sup> The calculation was also performed with the non-parametric Wilcoxon-Mann-Whitney test, which gives an achieved power of 99.9% with a sample size of 3 per group.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3-6"><title>Protocol 6</title><sec id="s3-6-1"><title>Summary of original data</title><list list-type="bullet"><list-item><p>Note: data estimated from the image reported in Figure 4F.<list list-type="bullet"><list-item><p>The original data presented is qualitative (images of Western blots). We used ImageJ version 1.50a (<xref ref-type="bibr" rid="bib36">Schneider et al., 2012</xref>) to perform densitometric analysis of the presented bands to quantify the original effect size where possible. The data presented in Figure 4F for Input MAP2K4 were unable to be quantified for all bands and were thus excluded from the normalization. Additionally, the WT values provide under-estimates of the actual values since the WT bands were saturated and unable to be quantified.</p></list-item></list></p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Variant</th><th>Normalized pJNK band intensity to WT</th><th>Normalized pMBP band intensity to WT</th></tr></thead><tbody><tr><td>WT</td><td>1</td><td>1</td></tr><tr><td>R228K</td><td>0.299736</td><td>0.057556</td></tr><tr><td>A279T</td><td>0.613378</td><td>0.096804</td></tr></tbody></table></table-wrap><list list-type="bullet"><list-item><p>The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.</p></list-item></list></sec><sec id="s3-6-2"><title>Test family</title><list list-type="bullet"><list-item><p><italic>t</italic>-test: Means: Difference from constant (one sample case): Bonferroni’s correction: alpha error = 0.0125.</p></list-item></list></sec><sec id="s3-6-3"><title>Power calculations</title><list list-type="bullet"><list-item><p>Performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib13">Faul et al., 2007</xref>).</p></list-item><list-item><p>2% variance</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Substrate</th><th>Variant</th><th>Constant (WT)</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Sample size per group</th></tr></thead><tbody><tr><td rowspan="2">P-JNK</td><td>R228K</td><td>1</td><td>116.813</td><td>99.9%</td><td>3</td></tr><tr><td>A279T</td><td>1</td><td>31.5157</td><td>99.9%</td><td>3</td></tr><tr><td rowspan="2">P-MBP</td><td>R228K</td><td>1</td><td>818.713</td><td>99.9%</td><td>3</td></tr><tr><td>A279T</td><td>1</td><td>466.507</td><td>99.9%</td><td>3</td></tr></tbody></table></table-wrap><list list-type="bullet"><list-item><p>15% variance</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Substrate</th><th>Variant</th><th>Constant (WT)</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Sample size per group</th></tr></thead><tbody><tr><td rowspan="2">P-JNK</td><td>R228K</td><td>1</td><td>15.5751</td><td>99.9%</td><td>3</td></tr><tr><td>A279T</td><td>1</td><td>4.20210</td><td>92.2%</td><td>4</td></tr><tr><td rowspan="2">P-MBP</td><td>R228K</td><td>1</td><td>109.162</td><td>99.9%</td><td>3</td></tr><tr><td>A279T</td><td>1</td><td>62.2009</td><td>99.9%</td><td>3</td></tr></tbody></table></table-wrap><list list-type="bullet"><list-item><p>28% variance</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Substrate</th><th>Variant</th><th>Constant (WT)</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Sample size per group</th></tr></thead><tbody><tr><td rowspan="2">P-JNK</td><td>R228K</td><td>1</td><td>8.34380</td><td>92.6%</td><td>3</td></tr><tr><td>A279T</td><td>1</td><td>2.25112</td><td>88.7%</td><td>6</td></tr><tr><td rowspan="2">P-MBP</td><td>R228K</td><td>1</td><td>58.4795</td><td>99.9%</td><td>3</td></tr><tr><td>A279T</td><td>1</td><td>33.3219</td><td>99.9%</td><td>3</td></tr></tbody></table></table-wrap><list list-type="bullet"><list-item><p>40% variance</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Substrate</th><th>Variant</th><th>Constant (WT)</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Sample size per group</th></tr></thead><tbody><tr><td rowspan="2">P-JNK</td><td>R228K</td><td>1</td><td>5.84066</td><td>99.5%</td><td>4</td></tr><tr><td>A279T</td><td>1</td><td>1.57579</td><td>82.5%</td><td>8</td></tr><tr><td rowspan="2">P-MBP</td><td>R228K</td><td>1</td><td>40.9357</td><td>99.9%</td><td>3</td></tr><tr><td>A279T</td><td>1</td><td>23.3254</td><td>99.9%</td><td>3</td></tr></tbody></table></table-wrap><list list-type="bullet"><list-item><p>Based on these ranges of variance, which use a conservative effect size estimate since the original data were unable to be quantified, we will run the experiment four times.</p></list-item></list></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The Reproducibility Project: Cancer Biology core team would like to thank the original authors, in particular Bijay Jaiswal, for generously sharing critical information to ensure the fidelity and quality of this replication attempt. We are grateful to Courtney Soderberg at the Center for Open Science for assistance with statistical analyses. We would also like to thank the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology; American Type Culture Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma-Aldrich, and System Biosciences (SBI).</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>VS the experiments presented in this manuscript will be conducted at Applied Biological Materials, which is a Science Exchange lab.</p></fn><fn fn-type="conflict" id="conf2"><p>LY the experiments presented in this manuscript will be conducted at Applied Biological Materials, which is a Science Exchange lab.</p></fn><fn fn-type="conflict" id="conf3"><p>The other authors declare that no competing interests exist.</p></fn><fn fn-type="conflict" id="conf4"><p>RP:CB employed by and holds shares in Science Exchange Inc.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>VS, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>LY, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>ABA, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>KO, Drafting or revising the article</p></fn><fn fn-type="con" id="con5"><p>RP:CB, Conception and design, Drafting or revising the article</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>Y-H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Gibbons</surname><given-names>DL</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Thilaganathan</surname><given-names>N</given-names></name><name><surname>Alvarez</surname><given-names>CA</given-names></name><name><surname>Roybal</surname><given-names>J</given-names></name><name><surname>Goldsmith</surname><given-names>EJ</given-names></name><name><surname>Tournier</surname><given-names>C</given-names></name><name><surname>Kurie</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor 2 expression</article-title><source>Molecular and Cellular Biology</source><volume>31</volume><fpage>4270</fpage><lpage>4285</lpage><pub-id pub-id-type="doi">10.1128/MCB.05562-11</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birnbaumer</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007a</year><article-title>The discovery of signal transduction by G proteins. a personal account and an overview of the initial findings and contributions that led to our present understanding</article-title><source>Biochimica Et Biophysica Acta</source><volume>1768</volume><fpage>756</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2006.09.027</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birnbaumer</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007b</year><article-title>Expansion of signal transduction by G proteins. The second 15 years or so: from 3 to 16 alpha subunits plus betagamma dimers</article-title><source>Biochimica Et Biophysica Acta</source><volume>1768</volume><fpage>772</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2006.12.002</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Mammalian MAP kinase signalling cascades</article-title><source>Nature</source><volume>410</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/35065000</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Translating insights from the cancer genome into clinical practice</article-title><source>Nature</source><volume>452</volume><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/nature06914</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Making sense of cancer genomic data</article-title><source>Genes &amp; Development</source><volume>25</volume><fpage>534</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1101/gad.2017311</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Green</surname><given-names>ED</given-names></name><name><surname>Guttmacher</surname><given-names>AE</given-names></name><name><surname>Guyer</surname><given-names>MS</given-names></name><collab>US National Human Genome Research Institute</collab></person-group><year iso-8601-date="2003">2003</year><article-title>A vision for the future of genomics research</article-title><source>Nature</source><volume>422</volume><fpage>835</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1038/nature01626</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>SP</given-names></name><name><surname>Chin</surname><given-names>SF</given-names></name><name><surname>Turashvili</surname><given-names>G</given-names></name><name><surname>Rueda</surname><given-names>OM</given-names></name><name><surname>Dunning</surname><given-names>MJ</given-names></name><name><surname>Speed</surname><given-names>D</given-names></name><name><surname>Lynch</surname><given-names>AG</given-names></name><name><surname>Samarajiwa</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Gräf</surname><given-names>S</given-names></name><name><surname>Ha</surname><given-names>G</given-names></name><name><surname>Haffari</surname><given-names>G</given-names></name><name><surname>Bashashati</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>R</given-names></name><name><surname>McKinney</surname><given-names>S</given-names></name><name><surname>Langerød</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Provenzano</surname><given-names>E</given-names></name><name><surname>Wishart</surname><given-names>G</given-names></name><name><surname>Pinder</surname><given-names>S</given-names></name><name><surname>Watson</surname><given-names>P</given-names></name><name><surname>Markowetz</surname><given-names>F</given-names></name><name><surname>Murphy</surname><given-names>L</given-names></name><name><surname>Ellis</surname><given-names>I</given-names></name><name><surname>Purushotham</surname><given-names>A</given-names></name><name><surname>Børresen-Dale</surname><given-names>AL</given-names></name><name><surname>Brenton</surname><given-names>JD</given-names></name><name><surname>Tavaré</surname><given-names>S</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Aparicio</surname><given-names>S</given-names></name><collab>METABRIC Group</collab></person-group><year iso-8601-date="2012">2012</year><article-title>The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups</article-title><source>Nature</source><volume>486</volume><fpage>346</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1038/nature10983</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Hunter</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Greenman</surname><given-names>C</given-names></name><name><surname>Bignell</surname><given-names>G</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>O'Meara</surname><given-names>S</given-names></name><name><surname>Avis</surname><given-names>T</given-names></name><name><surname>Barthorpe</surname><given-names>S</given-names></name><name><surname>Brackenbury</surname><given-names>L</given-names></name><name><surname>Buck</surname><given-names>G</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name><name><surname>Cole</surname><given-names>J</given-names></name><name><surname>Dicks</surname><given-names>E</given-names></name><name><surname>Edwards</surname><given-names>K</given-names></name><name><surname>Forbes</surname><given-names>S</given-names></name><name><surname>Gorton</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Halliday</surname><given-names>K</given-names></name><name><surname>Harrison</surname><given-names>R</given-names></name><name><surname>Hills</surname><given-names>K</given-names></name><name><surname>Hinton</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Kosmidou</surname><given-names>V</given-names></name><name><surname>Laman</surname><given-names>R</given-names></name><name><surname>Lugg</surname><given-names>R</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Perry</surname><given-names>J</given-names></name><name><surname>Petty</surname><given-names>R</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Shepherd</surname><given-names>R</given-names></name><name><surname>Small</surname><given-names>A</given-names></name><name><surname>Solomon</surname><given-names>H</given-names></name><name><surname>Stephens</surname><given-names>Y</given-names></name><name><surname>Tofts</surname><given-names>C</given-names></name><name><surname>Varian</surname><given-names>J</given-names></name><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>S</given-names></name><name><surname>Widaa</surname><given-names>S</given-names></name><name><surname>Yates</surname><given-names>A</given-names></name><name><surname>Brasseur</surname><given-names>F</given-names></name><name><surname>Cooper</surname><given-names>CS</given-names></name><name><surname>Flanagan</surname><given-names>AM</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Knowles</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name><name><surname>Looijenga</surname><given-names>LH</given-names></name><name><surname>Malkowicz</surname><given-names>B</given-names></name><name><surname>Pierotti</surname><given-names>MA</given-names></name><name><surname>Teh</surname><given-names>BT</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Lakhani</surname><given-names>SR</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Goldstraw</surname><given-names>P</given-names></name><name><surname>Nicholson</surname><given-names>AG</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Somatic mutations of the protein kinase gene family in human lung cancer</article-title><source>Cancer Research</source><volume>65</volume><fpage>7591</fpage><lpage>7595</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1855</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>SJ</given-names></name><name><surname>Choong</surname><given-names>DYH</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Ryland</surname><given-names>GL</given-names></name><name><surname>Campbell</surname><given-names>IG</given-names></name><name><surname>Gorringe</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Analysis of the mitogen-activated protein kinase kinase 4 (mAP2K4) tumor suppressor gene in ovarian cancer</article-title><source>BMC Cancer</source><volume>11</volume><fpage>173</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-11-173</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derijard</surname><given-names>B</given-names></name><name><surname>Raingeaud</surname><given-names>J</given-names></name><name><surname>Barrett</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>I</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Ulevitch</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms</article-title><source>Science</source><volume>267</volume><fpage>682</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1126/science.7839144</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>TM</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Gunn</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>FE</given-names></name><name><surname>Lomax</surname><given-names>J</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An open investigation of the reproducibility of cancer biology research</article-title><source>eLife</source><volume>3</volume><pub-id pub-id-type="doi">10.7554/eLife.04333</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>A-G</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behavior Research Methods</source><volume>39</volume><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/BF03193146</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finegan</surname><given-names>KG</given-names></name><name><surname>Tournier</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer</article-title><source>Cancer Research</source><volume>70</volume><fpage>5797</fpage><lpage>5806</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3669</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>SA</given-names></name><name><surname>Bhamra</surname><given-names>G</given-names></name><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Dawson</surname><given-names>E</given-names></name><name><surname>Kok</surname><given-names>C</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The catalogue of somatic mutations in cancer (cOSMIC)</article-title><source>Current Protocols in Human Genetics</source><volume>10</volume><pub-id pub-id-type="doi">10.1002/0471142905.hg1011s57</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Marcos</surname><given-names>M</given-names></name><name><surname>Ghosh</surname><given-names>P</given-names></name><name><surname>Farquhar</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular basis of a novel oncogenic mutation in GNAO1</article-title><source>Oncogene</source><volume>30</volume><fpage>2691</fpage><lpage>2696</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.645</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilman</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>G proteins: transducers of receptor-generated signals</article-title><source>Annual Review of Biochemistry</source><volume>56</volume><fpage>615</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.56.070187.003151</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenman</surname><given-names>C</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Dalgliesh</surname><given-names>GL</given-names></name><name><surname>Hunter</surname><given-names>C</given-names></name><name><surname>Bignell</surname><given-names>G</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>O’Meara</surname><given-names>S</given-names></name><name><surname>Vastrik</surname><given-names>I</given-names></name><name><surname>Schmidt</surname><given-names>EE</given-names></name><name><surname>Avis</surname><given-names>T</given-names></name><name><surname>Barthorpe</surname><given-names>S</given-names></name><name><surname>Bhamra</surname><given-names>G</given-names></name><name><surname>Buck</surname><given-names>G</given-names></name><name><surname>Choudhury</surname><given-names>B</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name><name><surname>Cole</surname><given-names>J</given-names></name><name><surname>Dicks</surname><given-names>E</given-names></name><name><surname>Forbes</surname><given-names>S</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Halliday</surname><given-names>K</given-names></name><name><surname>Harrison</surname><given-names>R</given-names></name><name><surname>Hills</surname><given-names>K</given-names></name><name><surname>Hinton</surname><given-names>J</given-names></name><name><surname>Jenkinson</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Mironenko</surname><given-names>T</given-names></name><name><surname>Perry</surname><given-names>J</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Richardson</surname><given-names>D</given-names></name><name><surname>Shepherd</surname><given-names>R</given-names></name><name><surname>Small</surname><given-names>A</given-names></name><name><surname>Tofts</surname><given-names>C</given-names></name><name><surname>Varian</surname><given-names>J</given-names></name><name><surname>Webb</surname><given-names>T</given-names></name><name><surname>West</surname><given-names>S</given-names></name><name><surname>Widaa</surname><given-names>S</given-names></name><name><surname>Yates</surname><given-names>A</given-names></name><name><surname>Cahill</surname><given-names>DP</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Goldstraw</surname><given-names>P</given-names></name><name><surname>Nicholson</surname><given-names>AG</given-names></name><name><surname>Brasseur</surname><given-names>F</given-names></name><name><surname>Looijenga</surname><given-names>L</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Chiew</surname><given-names>Y-E</given-names></name><name><surname>deFazio</surname><given-names>A</given-names></name><name><surname>Greaves</surname><given-names>MF</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Campbell</surname><given-names>P</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>M-H</given-names></name><name><surname>Khoo</surname><given-names>SK</given-names></name><name><surname>Teh</surname><given-names>BT</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Patterns of somatic mutation in human cancer genomes</article-title><source>Nature</source><volume>446</volume><fpage>153</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1038/nature05610</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haeusgen</surname><given-names>W</given-names></name><name><surname>Tueffers</surname><given-names>L</given-names></name><name><surname>Herdegen</surname><given-names>T</given-names></name><name><surname>Waetzig</surname><given-names>V</given-names></name><name><surname>waetzig, v</surname></name></person-group><year iso-8601-date="2014">2014</year><article-title>Map2k4δ — identification and functional characterization of a novel Map2k4 splice variant</article-title><source>Biochimica Et Biophysica Acta</source><volume>1843</volume><fpage>875</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.01.028</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helleday</surname><given-names>T</given-names></name><name><surname>Eshtad</surname><given-names>S</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mechanisms underlying mutational signatures in human cancers</article-title><source>Nature Reviews Genetics</source><volume>15</volume><fpage>585</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1038/nrg3729</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Che</surname><given-names>X</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Zhai</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zuo</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Dai</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Cheung</surname><given-names>ST</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer</article-title><source>Carcinogenesis</source><volume>34</volume><fpage>1001</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgt004</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jastrzebska</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>GPCR: g protein complexes—the fundamental signaling assembly</article-title><source>Amino Acids</source><volume>45</volume><fpage>1303</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.1007/s00726-013-1593-y</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>GL</given-names></name><name><surname>Lapadat</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases</article-title><source>Science</source><volume>298</volume><fpage>1911</fpage><lpage>1912</lpage><pub-id pub-id-type="doi">10.1126/science.1072682</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kan</surname><given-names>Z</given-names></name><name><surname>Jaiswal</surname><given-names>BS</given-names></name><name><surname>Stinson</surname><given-names>J</given-names></name><name><surname>Janakiraman</surname><given-names>V</given-names></name><name><surname>Bhatt</surname><given-names>D</given-names></name><name><surname>Stern</surname><given-names>HM</given-names></name><name><surname>Yue</surname><given-names>P</given-names></name><name><surname>Haverty</surname><given-names>PM</given-names></name><name><surname>Bourgon</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Moorhead</surname><given-names>M</given-names></name><name><surname>Chaudhuri</surname><given-names>S</given-names></name><name><surname>Tomsho</surname><given-names>LP</given-names></name><name><surname>Peters</surname><given-names>BA</given-names></name><name><surname>Pujara</surname><given-names>K</given-names></name><name><surname>Cordes</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>DP</given-names></name><name><surname>Carlton</surname><given-names>VEH</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Eigenbrot</surname><given-names>C</given-names></name><name><surname>Kaminker</surname><given-names>JS</given-names></name><name><surname>Eberhard</surname><given-names>DA</given-names></name><name><surname>Waring</surname><given-names>P</given-names></name><name><surname>Schuster</surname><given-names>SC</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Stokoe</surname><given-names>D</given-names></name><name><surname>de Sauvage</surname><given-names>FJ</given-names></name><name><surname>Faham</surname><given-names>M</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Diverse somatic mutation patterns and pathway alterations in human cancers</article-title><source>Nature</source><volume>466</volume><fpage>869</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1038/nature09208</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landis</surname><given-names>CA</given-names></name><name><surname>Masters</surname><given-names>SB</given-names></name><name><surname>Spada</surname><given-names>A</given-names></name><name><surname>Pace</surname><given-names>AM</given-names></name><name><surname>Bourne</surname><given-names>HR</given-names></name><name><surname>Vallar</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>GTPase inhibiting mutations activate the α chain of gs and stimulate adenylyl cyclase in human pituitary tumours</article-title><source>Nature</source><volume>340</volume><fpage>692</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1038/340692a0</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leyme</surname><given-names>A</given-names></name><name><surname>Marivin</surname><given-names>A</given-names></name><name><surname>Casler</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>LT</given-names></name><name><surname>Garcia-Marcos</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Different biochemical properties explain why two equivalent g subunit mutants cause unrelated diseases</article-title><source>Journal of Biological Chemistry</source><volume>289</volume><fpage>21818</fpage><lpage>21827</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.549790</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A functional variant (-1304T&gt;G) in the MKK4 promoter contributes to a decreased risk of lung cancer by increasing the promoter activity</article-title><source>Carcinogenesis</source><volume>31</volume><fpage>1405</fpage><lpage>1411</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgq126</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotan</surname><given-names>TL</given-names></name><name><surname>Lyon</surname><given-names>M</given-names></name><name><surname>Huo</surname><given-names>D</given-names></name><name><surname>Taxy</surname><given-names>JB</given-names></name><name><surname>Brendler</surname><given-names>C</given-names></name><name><surname>Foster</surname><given-names>BA</given-names></name><name><surname>Stadler</surname><given-names>W</given-names></name><name><surname>Rinker-Schaeffer</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia</article-title><source>The Journal of Pathology</source><volume>212</volume><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1002/path.2194</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyons</surname><given-names>J</given-names></name><name><surname>Landis</surname><given-names>C</given-names></name><name><surname>Harsh</surname><given-names>G</given-names></name><name><surname>Vallar</surname><given-names>L</given-names></name><name><surname>Grunewald</surname><given-names>K</given-names></name><name><surname>Feichtinger</surname><given-names>H</given-names></name><name><surname>Duh</surname><given-names>Q</given-names></name><name><surname>Clark</surname><given-names>O</given-names></name><name><surname>Kawasaki</surname><given-names>E</given-names></name><name><surname>Bourne</surname><given-names>H</given-names></name><name><surname>et</surname><given-names>al</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Two g protein oncogenes in human endocrine tumors</article-title><source>Science</source><volume>249</volume><fpage>655</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1126/science.2116665</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Nakayama</surname><given-names>N</given-names></name><name><surname>Davidson</surname><given-names>B</given-names></name><name><surname>Katabuchi</surname><given-names>H</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Shih</surname><given-names>le-Ming</given-names></name><name><surname>Wang</surname><given-names>T-L</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Homozygous deletion of MKK4 in ovarian serous carcinoma</article-title><source>Cancer Biology &amp; Therapy</source><volume>5</volume><fpage>630</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.4161/cbt.5.6.2675</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Wang</surname><given-names>T-L</given-names></name><name><surname>Samuels</surname><given-names>Y</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Cummins</surname><given-names>JM</given-names></name><name><surname>DeLong</surname><given-names>L</given-names></name><name><surname>Silliman</surname><given-names>N</given-names></name><name><surname>Ptak</surname><given-names>J</given-names></name><name><surname>Szabo</surname><given-names>S</given-names></name><name><surname>Willson</surname><given-names>JKV</given-names></name><name><surname>Markowitz</surname><given-names>S</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Colorectal cancer: mutations in a signalling pathway</article-title><source>Nature</source><volume>436</volume><fpage>792</fpage><pub-id pub-id-type="doi">10.1038/436792a</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavese</surname><given-names>JM</given-names></name><name><surname>Ogden</surname><given-names>IM</given-names></name><name><surname>Voll</surname><given-names>EA</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Jovanovic</surname><given-names>B</given-names></name><name><surname>Bergan</surname><given-names>RC</given-names></name><name><surname>Tang</surname><given-names>C-H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mitogen-activated protein kinase kinase 4 (mAP2K4) promotes human prostate cancer metastasis</article-title><source>PLoS ONE</source><volume>9</volume><elocation-id>e102289</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0102289</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>BA</given-names></name><name><surname>Kan</surname><given-names>Z</given-names></name><name><surname>Sebisanovic</surname><given-names>D</given-names></name><name><surname>Pujara</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Hong</surname><given-names>P</given-names></name><name><surname>Chow</surname><given-names>B</given-names></name><name><surname>Stinson</surname><given-names>J</given-names></name><name><surname>Carlton</surname><given-names>VEH</given-names></name><name><surname>Pham</surname><given-names>TQ</given-names></name><name><surname>Stern</surname><given-names>H</given-names></name><name><surname>Waring</surname><given-names>P</given-names></name><name><surname>Hillan</surname><given-names>KJ</given-names></name><name><surname>Eberhard</surname><given-names>DA</given-names></name><name><surname>de Sauvage</surname><given-names>F</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Faham</surname><given-names>M</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Highly efficient somatic-mutation identification using escherichia coli mismatch-repair detection</article-title><source>Nature Methods</source><volume>4</volume><fpage>713</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1038/nmeth1081</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeifer</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Environmental exposures and mutational patterns of cancer genomes</article-title><source>Genome Medicine</source><volume>2</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/gm175</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pleasance</surname><given-names>ED</given-names></name><name><surname>Stephens</surname><given-names>PJ</given-names></name><name><surname>O’Meara</surname><given-names>S</given-names></name><name><surname>McBride</surname><given-names>DJ</given-names></name><name><surname>Meynert</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>M-L</given-names></name><name><surname>Beare</surname><given-names>D</given-names></name><name><surname>Lau</surname><given-names>KW</given-names></name><name><surname>Greenman</surname><given-names>C</given-names></name><name><surname>Varela</surname><given-names>I</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>HR</given-names></name><name><surname>Ordoñez</surname><given-names>GR</given-names></name><name><surname>Mudie</surname><given-names>LJ</given-names></name><name><surname>Latimer</surname><given-names>C</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Stebbings</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>M</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Mangion</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>YA</given-names></name><name><surname>McLaughlin</surname><given-names>SF</given-names></name><name><surname>Peckham</surname><given-names>HE</given-names></name><name><surname>Tsung</surname><given-names>EF</given-names></name><name><surname>Costa</surname><given-names>GL</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Gazdar</surname><given-names>A</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Rhodes</surname><given-names>MD</given-names></name><name><surname>McKernan</surname><given-names>KJ</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A small-cell lung cancer genome with complex signatures of tobacco exposure</article-title><source>Nature</source><volume>463</volume><fpage>184</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/nature08629</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>CA</given-names></name><name><surname>Rasband</surname><given-names>WS</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NIH image to ImageJ: 25 years of image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>W-Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Feng</surname><given-names>N-H</given-names></name><name><surname>Hua</surname><given-names>L-X</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of the functional MKK4 promoter variant (−1304T&gt;G) in a decreased risk of prostate cancer: case–control study and meta-analysis</article-title><source>Journal of Cancer Research and Clinical Oncology</source><volume>138</volume><fpage>1531</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1007/s00432-012-1226-y</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The cancer genome</article-title><source>Nature</source><volume>458</volume><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/nature07943</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>GH</given-names></name><name><surname>Hilgers</surname><given-names>W</given-names></name><name><surname>Shekher</surname><given-names>MC</given-names></name><name><surname>Tang</surname><given-names>DJ</given-names></name><name><surname>Yeo</surname><given-names>CJ</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene</article-title><source>Cancer Research</source><volume>58</volume><fpage>2339</fpage><lpage>2342</lpage></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>GH</given-names></name><name><surname>Song</surname><given-names>JJ</given-names></name><name><surname>Repasky</surname><given-names>EA</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mutation rate of MAP2K4/MKK4 in breast carcinoma</article-title><source>Human Mutation</source><volume>19</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1002/humu.9002</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Team</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2014">2014</year><source>R: A Language and Environment for Statistical Computing</source><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>DH</given-names></name><name><surname>Perry</surname><given-names>WL</given-names></name><name><surname>Hogan</surname><given-names>JK</given-names></name><name><surname>Baumgard</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>R</given-names></name><name><surname>Berry</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>T</given-names></name><name><surname>Frank</surname><given-names>D</given-names></name><name><surname>Frye</surname><given-names>C</given-names></name><name><surname>Hattier</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Jammulapati</surname><given-names>S</given-names></name><name><surname>Janecki</surname><given-names>T</given-names></name><name><surname>Leavitt</surname><given-names>A</given-names></name><name><surname>Mitchell</surname><given-names>JT</given-names></name><name><surname>Pero</surname><given-names>R</given-names></name><name><surname>Sexton</surname><given-names>D</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>PH</given-names></name><name><surname>Swedlund</surname><given-names>B</given-names></name><name><surname>Kyriakis</surname><given-names>JM</given-names></name><name><surname>Avruch</surname><given-names>J</given-names></name><name><surname>Bartel</surname><given-names>P</given-names></name><name><surname>Wong</surname><given-names>AK</given-names></name><name><surname>Tavtigian</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor</article-title><source>Cancer Research</source><volume>57</volume><fpage>4177</fpage><lpage>4182</lpage></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Raamsdonk</surname><given-names>CD</given-names></name><name><surname>Bezrookove</surname><given-names>V</given-names></name><name><surname>Green</surname><given-names>G</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Gaugler</surname><given-names>L</given-names></name><name><surname>O’Brien</surname><given-names>JM</given-names></name><name><surname>Simpson</surname><given-names>EM</given-names></name><name><surname>Barsh</surname><given-names>GS</given-names></name><name><surname>Bastian</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi</article-title><source>Nature</source><volume>457</volume><fpage>599</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/nature07586</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors</article-title><source>Oncogene</source><volume>23</volume><fpage>5978</fpage><lpage>5985</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207802</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>IR</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Emerging patterns of somatic mutations in cancer</article-title><source>Nature Reviews Genetics</source><volume>14</volume><fpage>703</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1038/nrg3539</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lan</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The association between -1304T&gt;G polymorphism in the promoter of MKK4 gene and the risk of sporadic colorectal cancer in southern chinese population</article-title><source>International Journal of Cancer. Journal International Du Cancer</source><volume>125</volume><fpage>1876</fpage><lpage>1883</lpage><pub-id pub-id-type="doi">10.1002/ijc.24575</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Woo</surname><given-names>MS</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Perner</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>WM</given-names></name><name><surname>Province</surname><given-names>MA</given-names></name><name><surname>Kraja</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>RK</given-names></name><name><surname>Barletta</surname><given-names>JA</given-names></name><name><surname>Borecki</surname><given-names>IB</given-names></name><name><surname>Broderick</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>AC</given-names></name><name><surname>Chiang</surname><given-names>DY</given-names></name><name><surname>Chirieac</surname><given-names>LR</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Giordano</surname><given-names>T</given-names></name><name><surname>Greulich</surname><given-names>H</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Lash</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Lindeman</surname><given-names>N</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>McPherson</surname><given-names>JD</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Morgan</surname><given-names>MB</given-names></name><name><surname>Nadel</surname><given-names>M</given-names></name><name><surname>Orringer</surname><given-names>MB</given-names></name><name><surname>Osborne</surname><given-names>JR</given-names></name><name><surname>Ozenberger</surname><given-names>B</given-names></name><name><surname>Ramos</surname><given-names>AH</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Rusch</surname><given-names>V</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Shepherd</surname><given-names>F</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Tsao</surname><given-names>M-S</given-names></name><name><surname>Twomey</surname><given-names>D</given-names></name><name><surname>Verhaak</surname><given-names>RGW</given-names></name><name><surname>Weinstock</surname><given-names>GM</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Yoshizawa</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Zakowski</surname><given-names>MF</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Beer</surname><given-names>DG</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Watson</surname><given-names>MA</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Travis</surname><given-names>WD</given-names></name><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Characterizing the cancer genome in lung adenocarcinoma</article-title><source>Nature</source><volume>450</volume><fpage>893</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1038/nature06358</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeasmin</surname><given-names>S</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Rahman</surname><given-names>MT</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>M</given-names></name><name><surname>Katagiri</surname><given-names>A</given-names></name><name><surname>Iida</surname><given-names>K</given-names></name><name><surname>Nakayama</surname><given-names>N</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition</article-title><source>International Journal of Cancer</source><volume>128</volume><fpage>94</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1002/ijc.25332</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeasmin</surname><given-names>S</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Rahman</surname><given-names>MT</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>M</given-names></name><name><surname>Katagiri</surname><given-names>A</given-names></name><name><surname>Iida</surname><given-names>K</given-names></name><name><surname>Nakayama</surname><given-names>N</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>MKK4 acts as a potential tumor suppressor in ovarian cancer</article-title><source>Tumor Biology</source><volume>32</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1007/s13277-011-0166-5</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.11566.002</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hunter</surname><given-names>Tony</given-names></name><role>Reviewing editor</role><aff id="aff5"><institution>Salk Institute</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your work entitled &quot;Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers&quot; for consideration by <italic>eLife</italic>. Your submission has been evaluated by a Senior Editor, who would like you to revise the article as follows prior to peer review:</p><p>1) In the case of MAP2K4 there has been independent validation by others that the mutants lack kinase activity, and can drive transformation. In this regard, the authors have missed an important paper (Ahn et al. MCB 31:4270), where the authors examined the properties of 11 MAP2K4 cancer mutants for kinase activity and their ability to affect cell migration and invasion in culture, and alter autochthonous mutant KRas driven NSCLC tumor growth in vivo, reaching the conclusion that MAP2K4 acts as a tumor suppressor. We suggest that the authors add discussion of the Ahn et al. paper and review the literature on MAP2K4 mutations both prior to and subsequent to the Kan et al. paper in question, comprehensively, to ensure that there aren't any other omissions.</p><p>2) A technical issue relates to the authors' proposed use of inactive MAP2K7/JNK2 as a substrate for the in vitro MAP2K4 kinase assay. MAP2K7 (aka MKK7) is not the same as JNK2, and it is not a substrate for MAP2K4. This notation came from the original Kan et al. paper, but I suspect they mean MAPK9/JNK2, which is what the Invitrogen website lists under the PV3621 catalogue number they give. Could you check and correct this accordingly?</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><p>Thank you for submitting your work entitled &quot;Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Tony Hunter as the Senior Editor and Reviewing Editor. Two of the three reviewers, Somasekar Seshagiri and John Brognard, have agreed to share their names.</p><p>The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>As part of the Reproducibility Project: Cancer Biology, the authors will set out to replicate experimental data on mutant forms of GNAO1 and MAP2K4 that were published in Kan et al. (Nature 2010). The authors note that the functional relevance of the mutant forms of GNAO1 and MAP2K4 in cancer has been established by subsequent studies and propose to replicate the colony formation assay and kinase assay (MAP2K4) experiments reported in Kan et al. (Nature 2010). The authors describe the reagent generation, experimental work and analysis in great detail. The reviewers agree that the proposed plan is appropriate and closely adheres to published methods, but we have the following requests for revisions before publication of the Registered Report.</p><p>Essential revisions:</p><p>In the Registered Report, the authors use six protocols to replicate the experiments. For protocol 3, 5 and 6 power calculations and confirmatory analysis plans are described. In the confirmatory analysis plan of the protocol five One-way Anova is followed by planned comparisons using Fisher's LSD and in the corresponding power calculations for the t-tests a 0.05 α error is used. Fisher's LSD, however, does not control the family wise error rate (see Hayter, 1986) and it is useful only for the calculation of the effect size d. A Bonferroni correction should be used (α = 0.025. This issue needs to be addressed.</p><p>Reference: Anthony J Hayter. The maximum familywise error rate of Fisher's least significant difference test. Journal of the American Statistical Association, 81(396): 1000-1004, 1986. doi: 10.1080/01621459.1986.10478364</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.11566.003</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>1) In the case of MAP2K4 there has been independent validation by others that the mutants lack kinase activity, and can drive transformation. In this regard, the authors have missed an important paper (Ahn et al. MCB 31:4270), where the authors examined the properties of 11 MAP2K4 cancer mutants for kinase activity and their ability to affect cell migration and invasion in culture, and alter autochthonous mutant KRas driven NSCLC tumor growth</italic> in vivo<italic>, reaching the conclusion that MAP2K4 acts as a tumor suppressor. We suggest that the authors add discussion of the Ahn</italic> et al.</p><p> <italic>paper and review the literature on MAP2K4 mutations both prior to and subsequent to the Kan et al. paper in question, comprehensively, to ensure that there aren't any other omissions.</italic> </p><p>We have incorporated a discussion of this study (Ahn et al. 2011) into the Introduction. We have also added other citations to expand the state of knowledge about the function of MAP2K4 mutations.</p><p><italic>2) A technical issue relates to the authors' proposed use of inactive MAP2K7/JNK2 as a substrate for the</italic> in vitro <italic>MAP2K4 kinase assay. MAP2K7 (aka MKK7) is not the same as JNK2, and it is not a substrate for MAP2K4. This notation came from the original Kan et al. paper, but I suspect they mean MAPK9/JNK2, which is what the Invitrogen website lists under the PV3621 catalogue number they give. Could you check and correct this accordingly?</italic></p><p>We have made this change. The Invitrogen PV3621 MAPK9 is listed correctly listed in the reagents list.</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><p><italic>Essential revisions: In the Registered Report, the authors use six protocols to replicate the experiments. For protocol 3, 5 and 6 power calculations and confirmatory analysis plans are described. In the confirmatory analysis plan of the protocol five One-way Anova is followed by planned comparisons using Fisher's LSD and in the corresponding power calculations for the t-tests a 0.05 α error is used. Fisher's LSD, however, does not control the family wise error rate (see Hayter, 1986) and it is useful only for the calculation of the effect size d. A Bonferroni correction should be used (α</italic></p><p> <italic>= 0.025. This issue needs to be addressed. Reference: Anthony J Hayter. The maximum familywise error rate of Fisher's least significant difference test. Journal of the American Statistical Association, 81(396): 1000-1004, 1986. doi: 10.1080/01621459.1986.10478364</italic></p><p>We agree with the reviewers’ comment on the use of a correction, such as Bonferroni or the modification of LSD by Hayter as ways to control for the MFWER; however as Hayter describes in his 1986 paper, this applies in situations where the ANOVA is unbalanced or with a balanced design with four or more populations. Since the proposed analysis is balanced with three population groups, the LSD is sufficiently conservative and powerful to account for the multiple comparisons in this specific situation. This is further explained by Levin et al., 1994 and discussed in Maxwell and Delaney, 2004 (Chapter 5) and Cohen, 2001 (Chapter 12).</p><p>References:</p><p>Levin, J.R., Serline, R.C., &amp; Seaman M.A. (1994). A controlled, powerful multiple-comparison strategy for several situations. Psychological Bulletin<italic>, 115</italic>, 153-159.</p><p>Maxwell, S.E. &amp; Delaney, H.D. (2004). Designing experiments and analyzing data: a model comparison perspecitive. Lawrence Erlbaum Associates, Mahwah, N.J., 2<sup>nd</sup> edition.</p><p>Cohen, B.H. (2001). Explaining psychological statistics. John Wiley and Sons, New York, 2<sup>nd</sup> edition.</p></body></sub-article></article>